<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Transl Radiat Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Clin Transl Radiat Oncol</journal-id><journal-title-group><journal-title>Clinical and Translational Radiation Oncology</journal-title></journal-title-group><issn pub-type="epub">2405-6308</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC9440257</article-id><article-id pub-id-type="pii">S2405-6308(22)00073-8</article-id><article-id pub-id-type="doi">10.1016/j.ctro.2022.08.011</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Particle beam therapy for nasopharyngeal cancer: A systematic review and meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name><surname>Ng</surname><given-names>Wai Tong</given-names></name><xref rid="af005" ref-type="aff">a</xref><xref rid="af010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au010"><name><surname>But</surname><given-names>Barton</given-names></name><xref rid="af010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au015"><name><surname>Wong</surname><given-names>Charlene H.L.</given-names></name><email>wonghlc@hku.hk</email><xref rid="af010" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="au020"><name><surname>Choi</surname><given-names>Cheuk-Wai</given-names></name><xref rid="af015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au025"><name><surname>Chua</surname><given-names>Melvin L.K.</given-names></name><xref rid="af020" ref-type="aff">d</xref><xref rid="af025" ref-type="aff">e</xref><xref rid="af030" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au030"><name><surname>Blanchard</surname><given-names>Pierre</given-names></name><xref rid="af035" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au035"><name><surname>Lee</surname><given-names>Anne W.M.</given-names></name><xref rid="af005" ref-type="aff">a</xref><xref rid="af010" ref-type="aff">b</xref></contrib><aff id="af005"><label>a</label>Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China</aff><aff id="af010"><label>b</label>Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China</aff><aff id="af015"><label>c</label>Department of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China</aff><aff id="af020"><label>d</label>Department of Head and Neck and Thoracic Cancers, Division of Radiation Oncology, National Cancer Centre Singapore, Singapore</aff><aff id="af025"><label>e</label>Division of Medical Sciences, National Cancer Centre Singapore, Singapore</aff><aff id="af030"><label>f</label>Oncology Academic Programme, Duke-NUS Medical School, Singapore</aff><aff id="af035"><label>g</label>Department of Radiation Oncology, Gustave Roussy, Universit&#x000e9; Paris-Saclay, Villejuif, France</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding author. <email>wonghlc@hku.hk</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>23</day><month>8</month><year>2022</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>11</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>23</day><month>8</month><year>2022</year></pub-date><volume>37</volume><fpage>41</fpage><lpage>56</lpage><history><date date-type="received"><day>8</day><month>4</month><year>2022</year></date><date date-type="rev-recd"><day>10</day><month>8</month><year>2022</year></date><date date-type="accepted"><day>19</day><month>8</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; 2022 The Author(s)</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract abstract-type="author-highlights" id="ab005"><title>Highlights</title><p><list list-type="simple" id="l0005"><list-item id="o0005"><label>&#x02022;</label><p id="p0005">Particle beam therapy yields excellent short-term treatment outcomes among NPC patients.</p></list-item><list-item id="o0010"><label>&#x02022;</label><p id="p0010">Particle beam therapy is generally safe in primary and recurrent NPC patients, with &#x02265;G3 late toxicity rates of 20&#x000a0;% or less.</p></list-item><list-item id="o0015"><label>&#x02022;</label><p id="p0015">An approximately 5% mortality rate was reported among recurrent NPC patients.</p></list-item></list></p></abstract><abstract id="ab010"><sec><title>Background/purpose</title><p>A systematic review and meta-analysis were performed to better understand the benefits of particle beam therapy for nasopharyngeal cancer (NPC) treatment. The survival outcomes and toxicity of primary and recurrent NPC patients treated with proton or carbon ion beam therapy were investigated.</p></sec><sec><title>Method</title><p>PubMed, Scopus, and Embase were searched between 1 January 2007 to 3 November 2021. The inclusion and exclusion criteria included studies with either primary or recurrent NPC patients, sample size of &#x02265;10 patients, and proton or carbon ion beam therapy as interventions. Twenty-six eligible studies with a total of 1502 patients were included. We used a random-effect meta-analysis to examine the impact of particle beam therapy on primary NPC patients and qualitatively described the results among recurrent patients. The primary outcome was overall survival (OS), while secondary outcomes included progression-free survival (PFS), local control (LC) and toxicity.</p></sec><sec><title>Results</title><p>The pooled OS at 1-year, 2-year and 3-year and 5-year for primary NPC patients who received particle beam therapy were 96&#x000a0;% (95&#x000a0;% confidence interval (CI)&#x000a0;=&#x000a0;92&#x000a0;%-98&#x000a0;%), 93&#x000a0;% (95&#x000a0;% CI&#x000a0;=&#x000a0;83&#x000a0;%-97&#x000a0;%), 90&#x000a0;% (95&#x000a0;% CI&#x000a0;=&#x000a0;73&#x000a0;%-97&#x000a0;%) and 73&#x000a0;% (95&#x000a0;% CI&#x000a0;=&#x000a0;52&#x000a0;%-87&#x000a0;%) respectively. The pooled 1-year and 2-year PFS, and LC for these patients were above 90&#x000a0;%. For locally recurrent NPC patients, the 1-year OS rate ranged from 65&#x000a0;% to 92&#x000a0;%, while the 1-year LC rate ranged from 80&#x000a0;% to 88&#x000a0;%. Both proton and carbon ion beam therapy were generally safe among primary and recurrent patients, with &#x02265;G3 late toxicity rates of 20&#x000a0;% or less. Approximately a 5&#x000a0;% mortality rate was reported among recurrent patients.</p></sec><sec><title>Conclusions</title><p>This systematic review and meta-analysis demonstrated particle beam therapy has great potential in treating NPC, yielding excellent survival outcomes with low toxicity. However, further investigations are needed to assess the long-term outcomes and cost-effectiveness of this newer form of radiotherapy.</p></sec></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>Nasopharyngeal cancer</kwd><kwd>Particle beam therapy</kwd><kwd>Proton beam therapy</kwd><kwd>Carbon ion beam therapy</kwd></kwd-group></article-meta></front><body><sec id="s0005"><title>Introduction</title><p id="p0020">Nasopharyngeal cancer (NPC) is one of the commonest skull base tumors, with an estimated 133,354 new cases and 80,008 deaths in 2020 <xref rid="b0005" ref-type="bibr">[1]</xref>, <xref rid="b0010" ref-type="bibr">[2]</xref>. This is particularly prevalent in South East Asia, accounting for 77&#x000a0;% of cases around the globe <xref rid="b0010" ref-type="bibr">[2]</xref>.</p><p id="p0025">Due to its location, radiotherapy (RT) is a primary treatment modality where photon-based RT is the most widely used method, and it is usually delivered by intensity-modulation (i.e., intensity-modulated radiation therapy (IMRT)) <xref rid="b0015" ref-type="bibr">[3]</xref>. However, photon releases their energy throughout the beam pathway <xref rid="b0020" ref-type="bibr">[4]</xref>. Hence, adjacent normal tissues around the tumor may expose to a high radiation dose. This is particularly relevant to tumors located at the nasopharynx, where multiple organs (including salivary glands, optic nerves and chiasm, cochlea, brainstem, and temporal lobes) that are sensitive to radiation are located nearby. Such beam property will invariably lead to higher complications <xref rid="b0025" ref-type="bibr">[5]</xref>. To tackle this, enhancement of IMRT delivery techniques through arc therapy and tomotherapy has been able to steepen the dose gradients between tumor and normal tissues. Still, the magnitude of dosimetric improvement is limited by the intrinsic beam property of photons <xref rid="b0030" ref-type="bibr">[6]</xref>.</p><p id="p0030">Particle beam therapy, especially proton beam therapy (PBT) and carbon-ion beam therapy (CIBT), have gained significant attention recently because they can substantially reduce radiation dose to the organs at risk (OARs). This is because charged particles deliver the majority of their energy at the end of range (the Bragg peak), with a negligible dose afterward <xref rid="b0035" ref-type="bibr">[7]</xref>. Hence, decreasing the occurrence of side effects by minimizing the radiation dose to OARs before and beyond the tumor region. Early clinical evidence of the effects of PBT and CIBT for NPC is rapidly emerging. In this systematic review and meta-analysis, we aimed to synthesize and critically appraise all available clinical evidence on the effectiveness and safety of particle beam therapy for primary and recurrent NPC patients.</p></sec><sec id="s0010"><title>Method</title><sec id="s0015"><title>Protocol registration</title><p id="p0035">The study was reported in accordance with the Preferred Reporting Items for Systematic Review and meta-Analyses (PRISMA) <xref rid="b0040" ref-type="bibr">[8]</xref>. The protocol for the study was registered in the International Prospective Register of Systematic Reviews (PROSPERO) database (Registration number: &#x0201c;CRD42021291402&#x0201d;).</p></sec><sec id="s0020"><title>Eligibility criteria</title><p id="p0040">To be eligible for this systematic review, studies should be published in English or Chinese and satisfy the following criteria. NPC was defined as malignant epithelial tumors of the nasopharynx (including nasopharyngeal carcinoma, nasopharyngeal papillary adenocarcinoma, and salivary gland-type carcinomas) in accordance with the WHO histological classification <xref rid="b0045" ref-type="bibr">[9]</xref>. Patients with this diagnosis, either primary or locally recurrent NPC, were included. In contrast, tumors involving the nasal cavity or paranasal sinuses were excluded. Studies with a total sample size of less than ten were also ineligible.</p><p id="p0045">The use of particle beam therapy (including PBT, CIBT, or its combination with photon) as interventions for NPC was included. Studies might or might not include control, and if available, photon RT was regarded as eligible control.</p><p id="p0050">In this meta-analysis, eligible studies should report survival outcomes or toxicity in the intervention group. The primary outcome of this study was prespecified as the overall survival (OS), which was the only endpoint that was consistently reported. Secondary outcomes included progression-free survival (PFS), local control (LC), regional control, toxicity, homogeneity index, and conformity index. Available dosimetric information reported in these studies were also examined.</p></sec><sec id="s0025"><title>Literature search</title><p id="p0055">A systematic literature search was conducted to retrieve potential eligible studies published between 1 January 2007 to 3 November 2021 from PubMed, Scopus, and Embase. Details of the search strategy was shown in <xref rid="s0120" ref-type="sec">Supplementary File 1</xref>.</p></sec><sec id="s0030"><title>Literature selection, data extraction and risk of bias assessment</title><p id="p0060">Two reviewers (B.B. and C.H.L.W.) performed literature selection, conducted data extraction, and assessed the risk of bias of eligible studies independently. Disagreements were resolved through discussion and consensus between the two reviewers. A third reviewer (W.T.N.) was consulted for unresolved discrepancies.</p><p id="p0065">Title and abstract of potential studies were screened, and their full texts were assessed for eligibility. A list of included studies was generated. For duplicate studies, the single most comprehensive version was chosen for inclusion. Furthermore, systematic reviews identified from the search were examined to ensure that eligible studies were not omitted.</p><p id="p0070">Key information including authors, year of publication, country, sample size, patient characteristics, dose-related information, follow-up time, details of intervention, and results of all prespecified outcomes were extracted from each eligible study using a pre-designed data extraction table. For studies that only showed survival outcomes indirectly on Kaplan-Meier curves, the GetData Graph Digitizer was applied to digitize and extract the survival data at specific time points. Apart from the survival outcomes or toxicity, other results such as dose-related outcomes such as homogeneity index, conformity index, dose distribution, and dose-volume histogram were retrieved (<xref rid="t0005" ref-type="table">Table 1</xref>).<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>Characteristics of included studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Study (publication year; location)</th><th>Sample size</th><th>T stage</th><th>N stage</th><th>Stage</th><th>Age range (years) (median)</th><th>Primary/Recurrent NPC</th><th>Follow-up (months) (median)</th><th>Dose per fraction (median)</th><th>No. of fractions (median)</th><th>Prescribed dose (median)</th><th>Intervention</th><th>Control</th><th>Outcome measurements</th></tr></thead><tbody><tr><td>Abe, T. et al. (2018; Japan) <xref rid="b0150" ref-type="bibr">[30]</xref></td><td>43</td><td>T1: 1<break/>T2: 10<break/>T3: 6<break/>T4: 26</td><td>N0: 40<break/>N1: 3</td><td>N/A</td><td>38&#x02013;76<break/>(63)</td><td>Recurrent NPC<sup>a</sup>: 5<break/>Primary NPC<sup>a</sup>: 38</td><td>3&#x02013;125<break/>(30)</td><td>2.2&#x02013;4&#x000a0;Gy (RBE)</td><td>16&#x02013;32</td><td>57.6&#x02013;70.4&#x000a0;Gy (RBE)</td><td>CIBT</td><td>N/A</td><td>1. Survival outcomes: a. OS <break/>(2&#x000a0;years) b. PFS <break/>(2&#x000a0;years) c. LC <break/>(2&#x000a0;years)<break/>2. Safety outcomes:<break/>a. Toxicity<break/></td></tr><tr><td>Akbaba, S. et al. (2019a; Germany) <xref rid="b0135" ref-type="bibr">[27]</xref></td><td>26</td><td>T1: 2<break/>T2: 1<break/>T3: 7<break/>T4: 16</td><td>N0: 8<break/>N+: 14<break/>Nx: 4</td><td>AJCC 8th ed.:<break/>I: 1<break/>II: 1<break/>III: 6<break/>IVa: 15<break/>IVb: 3</td><td>28&#x02013;73<break/>(49)</td><td>Primary NPC</td><td>10&#x02013;97<break/>(40)</td><td>Mixed beam:<break/>IMRT: 2&#x000a0;Gy<break/>Carbon ion: 3&#x000a0;Gy</td><td>N/A</td><td>72&#x02013;74&#x000a0;Gy (RBE) (74&#x000a0;Gy (RBE))</td><td>Mixed beam: IMRT and active raster-scanning CIBT</td><td>N/A</td><td>1. Survival outcomes: a. OS <break/>(2&#x000a0;years, 5&#x000a0;years)<break/>b. LC (2&#x000a0;years, 5&#x000a0;years) c. Distant PFS <break/>(2&#x000a0;years, 5&#x000a0;years)<break/>2. Safety outcomes:<break/>a. Toxicity<break/>b. Gastrostomy tube dependency</td></tr><tr><td>Akbaba, S. et al. (2019b; Germany) <xref rid="b0130" ref-type="bibr">[26]</xref></td><td>59</td><td>T1: 2<break/>T2: 1<break/>T3: 5<break/>T4: 48<break/>Tx: 3</td><td>N0: 52<break/>N1: 1<break/>N2b: 2<break/>N2c: 1<break/>Nx: 3</td><td>N/A</td><td>19&#x02013;77<break/>(50)</td><td>Primary NPC<sup>b</sup></td><td>7&#x02013;106<break/>(32)</td><td>IMRT: 2&#x000a0;Gy<break/>CIBT: 3&#x000a0;Gy (RBE)</td><td>N/A</td><td>72&#x02013;74&#x000a0;Gy (RBE)<break/>(74&#x000a0;Gy (RBE))</td><td>Mixed beam: IMRT and active raster-scanning CIBT</td><td>N/A</td><td>1. Survival outcomes:<break/>a. OS (2&#x000a0;years, 5&#x000a0;years) b. LC <break/>(2&#x000a0;years, 5&#x000a0;years) c. Distant PFS <break/>(2&#x000a0;years, 5&#x000a0;years)<break/>2. Safety outcomes:<break/>a. Toxicity<break/></td></tr><tr><td>Alterio, D. et al. (2020; Italy) <xref rid="b0140" ref-type="bibr">[28]</xref></td><td>Intervention: 27<break/>Control: 17</td><td>Intervention:<break/>T3: 12<break/>T4: 15<break/>Control:<break/>T3: 10<break/>T4: 7</td><td>Intervention:<break/>N0: 4<break/>N1: 8<break/>N2: 15<break/>Control:<break/>N0: 5<break/>N1: 3<break/>N2: 9<break/></td><td>AJCC 7th ed.:<break/>Intervention:<break/>III: 12<break/>IVa: 15<break/>Control:<break/>III: 10<break/>IVa: 7</td><td>Intervention:<break/>18&#x02013;73<break/>(49)<break/>Control:<break/>35&#x02013;76<break/>(54)</td><td>Primary NPC</td><td>Intervention:<break/>7&#x02013;69<break/>(25)<break/>Control:<break/>6&#x02013;122<break/>(51)</td><td>2&#x000a0;Gy</td><td>N/A</td><td>Intervention: 64&#x02013;74&#x000a0;Gy<break/>(70&#x000a0;Gy)<break/>Control:<break/>68&#x02013;70&#x000a0;Gy<break/>(70&#x000a0;Gy)</td><td>Mixed beam: IMRT and PBT</td><td>IMRT</td><td>1. Survival outcomes:<break/>a. PFS (2&#x000a0;years) b. Local PFS <break/>(2&#x000a0;years)<break/>c. LC<break/>2. Safety outcomes:<break/>a. Toxicity<break/>b. Gastrostomy tube dependency</td></tr><tr><td>Chou Y.C. et al. (2021; Taiwan) <xref rid="b0170" ref-type="bibr">[34]</xref></td><td>Intervention: 80<break/>Control: 278</td><td>Intervention:<break/>T1: 32<break/>T2: 11<break/>T3: 19<break/>T4: 18<break/>Control:<break/>T1: 25<break/>T2: 8<break/>T3: 7<break/>T4: 14</td><td>Intervention:<break/>N0: 13<break/>N1: 39<break/>N2: 15<break/>N3: 13<break/>Control:<break/>N0: 10<break/>N1: 34<break/>N2: 12<break/>N3: 18</td><td>AJCC 8th ed.:<break/>Intervention:<break/>I: 8<break/>II: 21<break/>III: 19<break/>IV: 32<break/>Control:<break/>I: 9<break/>II: 21<break/>III: 16<break/>IV: 34</td><td>Intervention:<break/>23&#x02013;79<break/>(48)<break/>Control:<break/>27&#x02013;79<break/>(50)</td><td>Primary NPC</td><td>Intervention:<break/>18&#x02013;34<break/>(24)<break/>Control:<break/>18&#x02013;63<break/>(42)</td><td>2.12&#x000a0;Gy(RBE)</td><td>33</td><td>69.96&#x000a0;Gy (RBE)</td><td>IMPT</td><td>Volumetric modulated arc therapy</td><td>1. Survival outcomes: a. OS <break/>(2&#x000a0;years) b. PFS <break/>(2&#x000a0;years)<break/>2. Safety outcomes:<break/>a. Toxicity<break/>b. Nasogastric tube dependency<break/>c. Body weight loss</td></tr><tr><td>Dionisi, F. et al. (2019; Italy) <xref rid="b0145" ref-type="bibr">[29]</xref></td><td>17</td><td>T2: 1<break/>T3: 3<break/>T4: 12<break/>Missing: 1</td><td>N/A</td><td>AJCC (no ed.):<break/>II: 1<break/>III: 4<break/>IV: 12</td><td>37&#x02013;76<break/>(58)</td><td>Recurrent NPC</td><td>2&#x02013;41<break/>(10)</td><td>1.8&#x02013;2&#x000a0;Gy<break/>(2&#x000a0;Gy)</td><td>N/A</td><td>30.6&#x02013;66&#x000a0;Gy<break/>(60&#x000a0;Gy)</td><td>PBT</td><td>N/A</td><td>1. Survival outcomes: a. OS <break/>(18&#x000a0;months) b. LC <break/>(18&#x000a0;months)<break/>2. Safety outcomes:<break/>a. Toxicity<break/>3. Dose-related outcomes:<break/>a. Dose distribution</td></tr><tr><td>Gentile, M. et al. (2017; United States) <xref rid="b0055" ref-type="bibr">[11]</xref></td><td>14</td><td>T3: 1<break/>T4: 13</td><td>N/A</td><td>N/A</td><td>26&#x02013;71<break/>(52)</td><td>Primary NPC<sup>b</sup></td><td>24&#x02013;175<break/>(69)</td><td>1.8&#x02013;2.0&#x000a0;Gy (RBE)</td><td>N/A</td><td>CTV:<break/>68&#x02013;76&#x000a0;Gy (RBE)<break/>(73.8&#x000a0;Gy (RBE))</td><td>Mixed beam: PBT and 3D-CRT/IMRT</td><td>N/A</td><td>1. Survival outcomes:<break/>a. OS (5&#x000a0;years) b. Distant metastasis-free survival <break/>(2&#x000a0;years, 5&#x000a0;years)<break/>c. Locoregional control<break/>2. Safety outcomes:<break/>a. Toxicity<break/>b. Gastrostomy tube dependency</td></tr><tr><td>Holliday, E.B. et al. (2015; United States) <xref rid="b0060" ref-type="bibr">[12]</xref></td><td>Intervention: 10<break/>Control: 20</td><td>Intervention:<break/>T1: 4<break/>T2: 2<break/>T3: 2<break/>T4: 2<break/>Control:<break/>T1: 8<break/>T2: 3<break/>T3: 3<break/>T4: 6</td><td>Intervention:<break/>N0: 1<break/>N1: 3<break/>N2: 6<break/>Control:<break/>N0: 4<break/>N1: 3<break/>N2: 10<break/>N3: 3</td><td>WHO:<break/>Intervention:<break/>II/III: 9<break/>Unknown: 1<break/>Control:<break/>I: 2<break/>II/III: 15<break/>Unknown: 3</td><td>Intervention:<break/>18&#x02013;55<break/>(45)<break/>Control:<break/>39&#x02013;59<break/>(51)</td><td>Primary NPC</td><td>Intervention:<break/>IQR: 14&#x02013;29<break/>(22)<break/>Control:<break/>IQR: 17&#x02013;37<break/>(26)<break/></td><td>2&#x02013;2.12&#x000a0;Gy or Gy (RBE)</td><td>33&#x02013;35</td><td>70&#x02013;70&#x000a0;Gy (RBE) (70&#x000a0;Gy (RBE))</td><td>IMPT</td><td>IMRT</td><td>1. Safety outcomes:<break/>a. Toxicity<break/>b. Gastrostomy tube dependency<break/>2. Dose-related outcomes:<break/>a. Dose distribution</td></tr><tr><td>Hu, J. et al. (2018; China) <xref rid="b0100" ref-type="bibr">[20]</xref></td><td>75</td><td>T0: 4<break/>T1: 5<break/>T2: 11<break/>T3: 28<break/>T4: 27</td><td>N+: 22</td><td>AJCC 7th ed.:<break/>I/II: 17<break/>III/IVa/IVb: 58</td><td>17&#x02013;70<break/>(48)</td><td>Recurrent NPC</td><td>3&#x02013;30<break/>(15)</td><td>2&#x02013;3 GyE<break/>(3 GyE)</td><td>N/A</td><td>50&#x02013;66 GyE<break/>(57.5 GyE)</td><td>IMCT</td><td>N/A</td><td>1. Survival outcomes: a. OS <break/>(1&#x000a0;year) b. Disease specific survival <break/>(1&#x000a0;year) c. PFS <break/>(1&#x000a0;year) d. Local recurrence-free survival <break/>(1&#x000a0;year)<break/>e. Regional recurrence-free survival (1&#x000a0;year) f. Distant metastasis-free survival <break/>(1&#x000a0;year)<break/>2. Safety outcomes:<break/>a. Toxicity</td></tr><tr><td>Hu, J. et al. (2020a; China) <xref rid="b0105" ref-type="bibr">[21]</xref></td><td>206</td><td>T0: 20<break/>T1: 24<break/>T2: 26<break/>T3: 60<break/>T4: 76</td><td>N0: 140<break/>N1: 53<break/>N2: 8<break/>N3: 5</td><td>AJCC 7th/8th ed.:<break/>I: 17<break/>II: 50<break/>III: 60<break/>IV: 79</td><td>17&#x02013;73<break/>(49)</td><td>Recurrent NPC</td><td>2&#x02013;75<break/>(23)</td><td>2&#x02013;3 GyE<break/>(3 GyE)</td><td>N/A</td><td>50&#x02013;69 GyE<break/>(63 GyE)</td><td>CIBT</td><td>N/A</td><td>1. Survival outcomes: a. OS <break/>(2&#x000a0;years)<break/>b. LC (2&#x000a0;years) c. RC <break/>(2&#x000a0;years) d. Distant control <break/>(2&#x000a0;years)<break/>2. Safety outcomes:<break/>a. Toxicity</td></tr><tr><td>Hu, J. et al. (2020b; China) <xref rid="b0115" ref-type="bibr">[23]</xref></td><td>41</td><td>N/A</td><td>N/A</td><td>WHO:<break/>I/II: 13<break/>III/IVa/IVb: 28</td><td>29&#x02013;70<break/>(46)</td><td>Recurrent NPC</td><td>3&#x02013;43<break/>(15)</td><td>2.5&#x02013;3 GyE<break/>(3 GyE)</td><td>N/A</td><td>50&#x02013;64 GyE<break/>(60 GyE)</td><td>CIBT</td><td>N/A</td><td>1. Survival outcomes:a. OS <break/>(1&#x000a0;year)<break/>b. Local PFS (1&#x000a0;year)</td></tr><tr><td>Hu, J. et al. (2021; China) <xref rid="b0110" ref-type="bibr">[22]</xref></td><td>69</td><td>T1: 18<break/>T2: 10<break/>T3: 29<break/>T4: 12</td><td>N0: 5<break/>N1: 30<break/>N2: 22<break/>N3: 12</td><td>AJCC 8th ed.:<break/>I: 1<break/>II: 17<break/>III: 29<break/>IV: 22</td><td>14&#x02013;68<break/>(48)</td><td>Primary NPC</td><td>5&#x02013;62<break/>(32)</td><td>PTV1: 2&#x000a0;Gy<break/>PTV2: 1.8&#x000a0;Gy<break/>CIBT boost: 2.5&#x02013;3.5 GyE</td><td>IMRT: 28<break/>CIBT: 5&#x02013;6</td><td>PTV1: 56&#x000a0;Gy<break/>PTV2: 50.4&#x000a0;Gy<break/>CIBT boost: 15&#x02013;17.5 GyE</td><td>Mixed beam: IMRT with CIBT boost</td><td>N/A</td><td>1. Survival outcomes a. OS <break/>(3&#x000a0;years) b. PFS <break/>(3&#x000a0;years) c. LC <break/>(3&#x000a0;years) d. RC <break/>(3&#x000a0;years) e. Distant control <break/>(3&#x000a0;years)<break/>2. Safety outcomes:<break/>a. Toxicity<break/>b. Gastrostomy tube dependency</td></tr><tr><td>Hung, H.M. et al. (2021; Hong Kong) <xref rid="b0180" ref-type="bibr">[36]</xref></td><td>20</td><td>T3: 18<break/>T4: 2</td><td>N0: 14<break/>N1: 6</td><td>N/A</td><td>N/A</td><td>Recurrent NPC</td><td>N/A</td><td>N/A</td><td>N/A</td><td>60&#x000a0;Gy</td><td>IMPT</td><td>IMRT</td><td>1. Dose-related outcomes:<break/>a. Dose distribution<break/>b. Target coverage</td></tr><tr><td>Ji&#x00159;&#x000ed;, K. et al. (2021; Czech Republic) <xref rid="b0175" ref-type="bibr">[35]</xref></td><td>43</td><td>T1: 7<break/>T2: 12<break/>T3: 9<break/>T4: 15</td><td>N0: 3<break/>N1: 11<break/>N2: 25<break/>N3: 4</td><td>AJCC 7th ed.:<break/>II: 8<break/>III: 19<break/>IVa: 10<break/>IVb: 6</td><td>23&#x02013;73<break/>(47)</td><td>Primary NPC</td><td>2&#x02013;62<break/>(24)</td><td>2 GyE</td><td>35&#x02013;38<break/>(37)</td><td>70&#x02013;76 GyE<break/>(74 GyE)</td><td>IMPT with pencil beam scanning</td><td>N/A</td><td>1. Survival outcomes: a. OS <break/>(2&#x000a0;years) b. Disease-free survival <break/>(2&#x000a0;years) c. LC <break/>(2&#x000a0;years)<break/>2. Safety outcomes:<break/>a. Toxicity<break/>3. Dose-related outcomes:<break/>a. Dose distribution</td></tr><tr><td>Li, X. et al. (2021; United States) <xref rid="b0095" ref-type="bibr">[19]</xref></td><td>Intervention: 28<break/>Control: 49</td><td>Intervention:<break/>T1: 7<break/>T2: 3<break/>T3: 9<break/>T4: 8<break/>Tx: 1<break/>Control:<break/>T1: 21<break/>T2: 8<break/>T3: 14<break/>T4: 6</td><td>Intervention:<break/>N0: 7<break/>N1: 10<break/>N2: 10<break/>N3: 1<break/>Control:<break/>N0: 5<break/>N1: 23<break/>N2: 18<break/>N3: 3</td><td>AJCC 8th ed.:<break/>Intervention:<break/>I: 4<break/>II: 4<break/>III: 11<break/>IVa: 9<break/>Control:<break/>I: 3<break/>II: 13<break/>III: 25<break/>IVa: 8</td><td>Intervention:<break/>IQR: 42&#x02013;60<break/>(46)<break/>Control:<break/>IQR: 43&#x02013;61<break/>(50)</td><td>Primary NPC</td><td>Intervention:<break/>IQR: 14&#x02013;30<break/>(19)<break/>Control:<break/>IQR: 26&#x02013;44<break/>(37)</td><td>N/A</td><td>69.96, 56.0&#x02013;59.4 and 54.12 GyE:<break/>33<break/>70.0, 59.0&#x02013;63.0 and 56.0 GyE: 35<break/></td><td>Intervention:<break/>IQR:<break/>69.96&#x02013;70.0 GyE<break/>(70.0 GyE)<break/>Control:<break/>IQR:<break/>69.96&#x02013;69.96 GyE<break/>(69.96 GyE)<break/></td><td>IMPT</td><td>IMRT</td><td>1. Survival outcomes: a. OS <break/>(3&#x000a0;years) b. PFS <break/>(2&#x000a0;years) c. Locoregional failure-free survival <break/>(2&#x000a0;years)<break/>2. Safety outcomes:<break/>a. Toxicity<break/>b. Gastrostomy tube dependency</td></tr><tr><td>Ma, G. et al. (2021; China) <xref rid="b0120" ref-type="bibr">[24]</xref></td><td>29</td><td>N/A</td><td>N/A</td><td>AJCC 7th ed.:<break/>I/II: 10<break/>III/IVa: 19</td><td>29&#x02013;69<break/>(47)</td><td>Recurrent NPC</td><td>N/A<break/>(37)</td><td>2&#x02013;3 GyE</td><td>N/A</td><td>50&#x02013;65 GyE</td><td>CIBT</td><td>N/A</td><td>1. Survival outcomes: a. Local recurrence-free survival <break/>(1&#x000a0;year) b. PFS <break/>(1&#x000a0;year)<break/>2. Prognosis performance:<break/>a. AUC<break/>b. Sensitivity<break/>c. Specificity<break/></td></tr><tr><td>Minatogawa, H. et al. (2021; Japan) <xref rid="b0155" ref-type="bibr">[31]</xref></td><td>10</td><td>T1: 4<break/>T2: 2<break/>T3: 4</td><td>N0: 1<break/>N1: 5<break/>N2: 4</td><td>AJCC 7th ed.:<break/>II: 3<break/>III: 7</td><td>57&#x02013;73<break/>(62)</td><td>Primary NPC</td><td>N/A</td><td>2&#x000a0;Gy</td><td>Total: 35<break/>Initial plan: 23<break/>Adaptive plan: 12</td><td>Initial plan: 46&#x000a0;Gy<break/>Adaptive plan: 24&#x000a0;Gy</td><td>Adaptive IMPT with spot scanning</td><td>N/A</td><td>1. Dose-related outcomes:<break/>a. Dose distribution<break/>b. Conformation number<break/>c. Homogeneity index<break/>d. Dose volume histogram</td></tr><tr><td>Nam, H. et al. (2021; South Korea) <xref rid="b0160" ref-type="bibr">[32]</xref></td><td>60</td><td>T1-2: 31<break/>T3-4: 29</td><td>N0-1: 56<break/>N2-3: 4</td><td>N/A</td><td>28&#x02013;79<break/>(53)</td><td>Recurrent NPC</td><td>2&#x02013;254<break/>(22)</td><td>2.3&#x02013;4.0&#x000a0;Gy<break/>(3.0&#x000a0;Gy)</td><td>N/A</td><td>40&#x02013;70&#x000a0;Gy<break/>(60&#x000a0;Gy)</td><td>IMPT/ IMRT/ 3D-CRT</td><td>N/A</td><td>1. Survival outcome: a. OS <break/>(2&#x000a0;years, 5&#x000a0;years) b. Local failure-free survival <break/>(2&#x000a0;years, 5&#x000a0;years) c. Toxicity free survival <break/>(&#x02265;Grade 5 (2&#x000a0;years, 5&#x000a0;years)<break/>2. Safety outcome:<break/>a. Toxicity</td></tr><tr><td>Park, S.G. et al. (2019; South Korea) <xref rid="b0165" ref-type="bibr">[33]</xref></td><td>Intervention: 35<break/>Control: 63</td><td>N/A</td><td>N/A</td><td>AJCC 7th ed.:<break/>Intervention:<break/>II: 16<break/>III: 8<break/>IV: 11<break/>Control:<break/>II: 8<break/>III: 23<break/>IV: 32</td><td>Intervention:<break/>24&#x02013;66<break/>(50)<break/>Control:<break/>19&#x02013;80<break/>(51)</td><td>Primary NPC</td><td>5&#x02013;33<break/>(14)</td><td>GTV: 2.2&#x000a0;Gy (18 fractions)&#x000a0;+&#x000a0;2.4&#x000a0;Gy (12 fractions)<break/>High-risk CTV: 2&#x000a0;Gy<break/>Low-risk CTV: 2&#x000a0;Gy</td><td>GTV: 30<break/>High-risk CTV: 30<break/>Low-risk CTV: 18</td><td>GTV: 68.4&#x000a0;Gy<break/>High-risk CTV: 60&#x000a0;Gy<break/>Low-risk CTV: 36&#x000a0;Gy</td><td>Mixed beam:<break/>HT and IMPT</td><td>HT</td><td>1. Survival outcomes: a. PFS <break/>(1&#x000a0;year)<break/>2. Safety outcomes:<break/>a. Toxicity<break/>b. Gastrostomy tube dependency<break/>c. Dose volume histogram</td></tr><tr><td>Sanford, N.N. et al. (2019; United States) <xref rid="b0065" ref-type="bibr">[13]</xref></td><td>Intervention: 61<break/>Control: 12</td><td>T1: 10<break/>T2: 10<break/>T3: 15<break/>T4: 38</td><td>N/A</td><td>AJCC 7th ed.:<break/>Intervention and control:<break/>I: 2<break/>II: 7<break/>III: 21<break/>IV: 43</td><td>All patients:<break/>14&#x02013;78<break/>(51)</td><td>Primary NPC</td><td>N/A<break/>(90)</td><td>N/A<break/>(2&#x000a0;Gy)</td><td>(35)</td><td>GTV: 70&#x02013;76&#x000a0;Gy<break/>(70&#x000a0;Gy)</td><td>Double-scattered PBT</td><td>IMRT</td><td>1. Survival outcomes<sup>c</sup>: a. OS <break/>(2&#x000a0;years, 5&#x000a0;years, 7&#x000a0;years) b. Disease-free survival <break/>(2&#x000a0;years, 5&#x000a0;years, 7&#x000a0;years) c. LC <break/>(2&#x000a0;years, 5&#x000a0;years, 7&#x000a0;years) d. RC <break/>(2&#x000a0;years, 5&#x000a0;years, 7&#x000a0;years)<break/>2. Safety outcomes:<break/>a. Toxicity<break/>3. Dose-related outcomes:<break/>a. Dose distribution</td></tr><tr><td>Sasidharan, B. K. et al. (2019; United States) <xref rid="b0070" ref-type="bibr">[14]</xref></td><td>14</td><td>N/A</td><td>N/A</td><td>N/A</td><td>IQR: 46&#x02013;63<break/>(58)</td><td>Primary NPC</td><td>&#x02265;3</td><td>N/A</td><td>33</td><td>PTV (high risk): 66&#x02013;70&#x000a0;Gy(RBE) PTV <break/>(intermediate risk): 60&#x02013;63&#x000a0;Gy(RBE) PTV <break/>(low risk): 54&#x000a0;Gy(RBE)</td><td>IMPT with pencil beam scanning</td><td>N/A</td><td>1. Dose-related outcomes:<break/>a. Dose distribution b. Conformity index (PTV (high risk)<break/>) c. Homogeneity index (PTV high risk)<break/>)<break/>d. Dose volume histogram</td></tr><tr><td>Shusharina, N. et al. (2019; United States) <xref rid="b0075" ref-type="bibr">[15]</xref></td><td>14<break/>NPC: 9<break/>Others: 5</td><td>T1: 1<break/>T2: 2<break/>T3: 1<break/>T4: 10</td><td>N0: 6<break/>N1: 3<break/>N2: 4<break/>N3: 1</td><td>AJCC (no ed.):<break/>I: 1<break/>II: 1<break/>III: 1<break/>IVa: 11</td><td>25&#x02013;69<break/>(56)</td><td>Primary NPC</td><td>N/A</td><td>2&#x000a0;Gy(RBE)</td><td>13 patients: 35<break/>1 patient: 31</td><td>GTV:<break/>70&#x000a0;Gy(RBE)<break/>1 patient: 62&#x000a0;Gy(RBE)</td><td>Passive-scattered PBT</td><td>N/A</td><td>1. Dose-related outcomes:<break/>a. Dose distribution</td></tr><tr><td>Uezono, H. et al. (2019; United States) <xref rid="b0080" ref-type="bibr">[16]</xref></td><td>17</td><td>T1: 1<break/>T2: 5<break/>T3: 2<break/>T4: 9</td><td>N1: 6<break/>N2: 9<break/>N3a: 2</td><td>AJCC 8th ed.:<break/>II: 1<break/>III: 6<break/>IVa: 8<break/>IVb: 2</td><td>7&#x02013;21<break/>(15)</td><td>Primary NPC</td><td>19&#x02013;95<break/>(36)<break/></td><td>1.8&#x000a0;Gy</td><td>N/A</td><td>59.4&#x02013;61.2&#x000a0;Gy (61.2&#x000a0;Gy)</td><td>Double-scattered PBT</td><td>N/A</td><td>1. Survival outcomes: a. OS <break/>(3&#x000a0;years) b. PFS <break/>(3&#x000a0;years) c. LC <break/>(3&#x000a0;years)<break/>2. Safety outcomes:<break/>a. Toxicity<break/>b. Gastrostomy tube<break/>3. Dose-related outcomes:<break/>a. Dose distribution<break/>b. Conformity index<break/>c. Homogeneity index</td></tr><tr><td>Wang, L. et al. (2019; China) <xref rid="b0125" ref-type="bibr">[25]</xref></td><td>10</td><td>T0: 1<break/>T2: 1<break/>T3: 3<break/>T4: 5</td><td>N0: 7<break/>N1: 2<break/>N2: 1</td><td>AJCC 7th ed.:<break/>II: 2<break/>III: 3<break/>IVa: 5</td><td>33&#x02013;70<break/>(44)</td><td>Recurrent NPC</td><td>N/A</td><td>2.5&#x02013;3 GyE<break/>(3 GyE)</td><td>19&#x02013;24<break/>(20)</td><td>57&#x02013;60 GyE<break/>(60 GyE)</td><td>IMCT with pencil beam scanning</td><td>IMRT</td><td>1. Dose-related outcomes:<break/>a. Dose distribution<break/>b. Dose volume histogram<break/></td></tr><tr><td>Williams, V.M. et al. (2021; United States) <xref rid="b0085" ref-type="bibr">[17]</xref></td><td>26</td><td>T1: 5<break/>T2: 5<break/>T3: 1<break/>T4: 15</td><td>N0: 2<break/>N1: 10<break/>N2: 11<break/>N3: 3</td><td>AJCC 8th ed.:<break/>II: 2<break/>III: 7<break/>IVa: 17</td><td>19&#x02013;73<break/>(48)</td><td>Primary NPC</td><td>4&#x02013;60<break/>(25)</td><td>22 patients: 2.12&#x000a0;Gy(RBE)<break/>4 patients: 1.2&#x000a0;Gy(RBE)</td><td>22 patients: 33<break/>4 patients: 55&#x02013;60</td><td>22 patients: 70&#x000a0;Gy(RBE)<break/>4 patients: 66&#x02013;72&#x000a0;Gy(RBE)</td><td>IMPT with pencil beam scanning</td><td>N/A</td><td>1. Survival outcomes: a. OS <break/>(2&#x000a0;years) b. Locoregional control <break/>(2&#x000a0;years) c. Distant metastasis <break/>(2&#x000a0;years)<break/>2. Safety outcomes:<break/>a. Toxicity<break/>b. Gastrostomy tube dependency<break/>3. Dose-related outcomes:<break/>a. Dose distribution</td></tr><tr><td>Zhang, Y.Y. et al. (2021; United States) <xref rid="b0090" ref-type="bibr">[18]</xref></td><td>Intervention: 9<break/>Control:<break/>20</td><td>Intervention:<break/>T1: 1<break/>T2: 1<break/>T3: 2<break/>T4: 5<break/>Control: N/A</td><td>N/A</td><td>N/A</td><td>Intervention:<break/>19&#x02013;63<break/>(51)<break/>Control:<break/>N/A<break/>(43)</td><td>Primary NPC</td><td>Intervention:<break/>N/A<break/>(73)<break/>Control:<break/>N/A<break/>(66)</td><td>2&#x000a0;Gy(RBE)</td><td>35</td><td>Intervention:<break/>70&#x000a0;Gy(RBE)<break/>Control:<break/>71.5&#x000a0;Gy(BED)</td><td>Double-scattered PBT</td><td>IMRT</td><td>1. Dose-related outcomes:<break/>a. Dose distribution<break/>b. Tolerance dose<break/>c. Dose volume histogram</td></tr></tbody></table><table-wrap-foot><fn id="sp0045"><p>Remarks: <sup>a</sup>80% of patients included in this study fulfilled the WHO histological subtypes of NPC; <sup>b</sup>Patients with salivary gland-type carcinomas of nasopharynx; <sup>c</sup>Outcome of intervention cohort cannot be extracted.</p></fn><fn id="sp0050"><p>Abbreviations: 3D-CRT, three-dimensional conformal radiation therapy; AUC, area under the receiver operating characteristic curve; BED, biological effective dose; CIBT, carbon ion beam therapy; CTV, clinical target volume; GTV, gross tumour volume; GyE, gray equivalent; HT, helical tomotherapy; IMCT, intensity-modulated carbon-ion radiation therapy; IMPT, intensity modulated proton therapy; IMRT, intensity-modulated radiation therapy; IQR, interquartile range; LC, local control; NPC, nasopharyngeal cancer; OS, overall survival; PBT, proton beam therapy; PFS, progression-free survival; PTV, planning target volume; RBE, relative biological effectiveness; RC, regional control.</p></fn></table-wrap-foot></table-wrap></p><p id="p0075">Risks of bias of all included studies were assessed using Cochrane&#x02019;s Risk of Bias in Non-Randomized Studies of Interventions tool <xref rid="b0050" ref-type="bibr">[10]</xref>. The risk of bias was categorised as low, moderate, serious, and critical risk of bias.</p></sec><sec id="s0035"><title>Data synthesis</title><p id="p0080">To examine the impact of PBT or CIBT on primary NPC patients, a random-effect model meta-analysis was performed to synthesize data on survival outcomes and toxicity using R version 4.1.1. The level of heterogeneity was measured with <italic>I</italic><sup>2</sup> statistics. Sensitivity analyses were conducted on the primary outcome of OS by excluding studies with patients having nasopharyngeal papillary adenocarcinoma and salivary gland-type carcinomas of the nasopharynx. Subgroup analyses were also performed on the primary outcome by stratifying studies based on different types of radiotherapy. Details on the use of particle beam therapy among locally recurrent NPC patients were described qualitatively.</p></sec></sec><sec id="s0040"><title>Results</title><sec id="s0045"><title>Literature search and selection</title><p id="p0085">The literature search yielded a total of 491 citations. After deduplication, title and abstract of 275 citations were screened, and 143 were excluded. Since full texts of 2 articles were not available, only 130 remaining papers were assessed for eligibility. Among these 130 studies, one hundred and five were excluded due to: i) not evaluating PBT or CIBT among NPC patients (n&#x000a0;=&#x000a0;65); ii) total sample size less than ten (n&#x000a0;=&#x000a0;8); and iii) not reporting any of the prespecified outcomes (n&#x000a0;=&#x000a0;32). With the identification of one eligible study from an existing systematic review, a total of 26 papers were included. Details of the literature search and selection of studies are presented in the Preferred Reporting Items for Systematic Review and meta-Analyses (PRISMA) flow diagram (<xref rid="f0005" ref-type="fig">Fig. 1</xref>) <xref rid="b0040" ref-type="bibr">[8]</xref>.<fig id="f0005"><label>Fig. 1</label><caption><p>PRISMA flow diagram <xref rid="b0040" ref-type="bibr">[8]</xref>.</p></caption><graphic xlink:href="gr1"/></fig></p></sec><sec id="s0050"><title>Characteristics of included studies</title><sec id="s0055"><title>Publication year and locations</title><p id="p0090">Characteristics of the 26 included studies are presented in <xref rid="t0005" ref-type="table">Table 1</xref>. All the included studies were published from 2015 to 2021, with majority of them being published between 2019 and 2021 (n&#x000a0;=&#x000a0;22). Among these included studies, nine were conducted in the United States <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0070" ref-type="bibr">[14]</xref>, <xref rid="b0075" ref-type="bibr">[15]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0090" ref-type="bibr">[18]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref> and 6 in China <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0115" ref-type="bibr">[23]</xref>, <xref rid="b0120" ref-type="bibr">[24]</xref>, <xref rid="b0125" ref-type="bibr">[25]</xref>. The remaining studies were conducted in Germany (n&#x000a0;=&#x000a0;2) <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, Italy (n&#x000a0;=&#x000a0;2) <xref rid="b0140" ref-type="bibr">[28]</xref>, <xref rid="b0145" ref-type="bibr">[29]</xref>, Japan (n&#x000a0;=&#x000a0;2) <xref rid="b0150" ref-type="bibr">[30]</xref>, <xref rid="b0155" ref-type="bibr">[31]</xref>, South Korea (n&#x000a0;=&#x000a0;2) <xref rid="b0160" ref-type="bibr">[32]</xref>, <xref rid="b0165" ref-type="bibr">[33]</xref>, Taiwan (n&#x000a0;=&#x000a0;1) <xref rid="b0170" ref-type="bibr">[34]</xref>, Czech Republic (n&#x000a0;=&#x000a0;1) <xref rid="b0175" ref-type="bibr">[35]</xref> and Hong Kong (n&#x000a0;=&#x000a0;1) <xref rid="b0180" ref-type="bibr">[36]</xref>.</p></sec><sec id="s0060"><title>Participants</title><p id="p0095">The 26 studies included a total of 1502 NPC patients, with sample sizes varying from 10 to 358. Seven papers had a patient size of 50 or more <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0160" ref-type="bibr">[32]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref>, and only one of them had a sample size of more than 100 <xref rid="b0105" ref-type="bibr">[21]</xref> (<xref rid="t0005" ref-type="table">Table 1</xref>). By definition of NPC in this systematic review, seventeen studies included patients with primary <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0070" ref-type="bibr">[14]</xref>, <xref rid="b0075" ref-type="bibr">[15]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0090" ref-type="bibr">[18]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref>, <xref rid="b0155" ref-type="bibr">[31]</xref>, <xref rid="b0165" ref-type="bibr">[33]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref> and 8 included recurrent NPC <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0115" ref-type="bibr">[23]</xref>, <xref rid="b0120" ref-type="bibr">[24]</xref>, <xref rid="b0125" ref-type="bibr">[25]</xref>, <xref rid="b0145" ref-type="bibr">[29]</xref>, <xref rid="b0160" ref-type="bibr">[32]</xref>, <xref rid="b0180" ref-type="bibr">[36]</xref>. The remaining study included both <xref rid="b0150" ref-type="bibr">[30]</xref>. Amongst these 26 included studies, two comprised patients entirely with salivary gland-type carcinomas of nasopharynx <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, whereas in another study <xref rid="b0150" ref-type="bibr">[30]</xref>, this histological subtype accounted for 80&#x000a0;% of patients. Seventeen studies used the American Joint Committee on Cancer (AJCC) system as the staging system for NPC (AJCC seventh edition in 8 studies, eighth edition in 6 studies, one used both, and 2 studies did not specify the version). After excluding a study where the patient proportion of the intervention cannot be quantified, 74&#x000a0;% of patients were classified as stage III and IV cancer. The median age range of patients was from 15 to 63&#x000a0;years and the median follow-up period ranged from 10 to 90&#x000a0;months.</p></sec><sec id="s0065"><title>Interventions and controls</title><p id="p0100">Moreover, thirteen studies used PBT as the intervention <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0070" ref-type="bibr">[14]</xref>, <xref rid="b0075" ref-type="bibr">[15]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0090" ref-type="bibr">[18]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0145" ref-type="bibr">[29]</xref>, <xref rid="b0155" ref-type="bibr">[31]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>, <xref rid="b0180" ref-type="bibr">[36]</xref>, while 6 studies treated patients with CIBT <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0115" ref-type="bibr">[23]</xref>, <xref rid="b0120" ref-type="bibr">[24]</xref>, <xref rid="b0125" ref-type="bibr">[25]</xref>, <xref rid="b0150" ref-type="bibr">[30]</xref>. The other 6 studies used a mixed beam approach, combining photon plus PBT or CIBT <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref>, <xref rid="b0165" ref-type="bibr">[33]</xref>. The remaining one grouped patients using either photon alone or PBT alone in its investigation <xref rid="b0160" ref-type="bibr">[32]</xref>. Hence, PBT was the most common intervention for NPC patients in this systematic review (<xref rid="t0005" ref-type="table">Table 1</xref>). It was also found that, amongst the 9 studies with control interventions, the majority used IMRT (n&#x000a0;=&#x000a0;7) <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0090" ref-type="bibr">[18]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0125" ref-type="bibr">[25]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref>, <xref rid="b0180" ref-type="bibr">[36]</xref> as the control, while one used volumetric modulated arc therapy <xref rid="b0170" ref-type="bibr">[34]</xref> and one used helical tomotherapy <xref rid="b0165" ref-type="bibr">[33]</xref> (<xref rid="t0005" ref-type="table">Table 1</xref>).</p></sec><sec id="s0070"><title>Outcomes</title><p id="p0105">Among the 26 included studies, nineteen reported prespecified survival outcomes, including OS (n&#x000a0;=&#x000a0;16) <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0115" ref-type="bibr">[23]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0145" ref-type="bibr">[29]</xref>, <xref rid="b0150" ref-type="bibr">[30]</xref>, <xref rid="b0160" ref-type="bibr">[32]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>, PFS (n&#x000a0;=&#x000a0;9) <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0120" ref-type="bibr">[24]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref>, <xref rid="b0150" ref-type="bibr">[30]</xref>, <xref rid="b0165" ref-type="bibr">[33]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref>, LC (n&#x000a0;=&#x000a0;10) <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref>, <xref rid="b0145" ref-type="bibr">[29]</xref>, <xref rid="b0150" ref-type="bibr">[30]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>, and regional control (n&#x000a0;=&#x000a0;3) <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>. Eighteen studies reported toxicity <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref>, <xref rid="b0145" ref-type="bibr">[29]</xref>, <xref rid="b0150" ref-type="bibr">[30]</xref>, <xref rid="b0160" ref-type="bibr">[32]</xref>, <xref rid="b0165" ref-type="bibr">[33]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>, while 12 articles reported dose-related outcomes, such as dose distribution (n&#x000a0;=&#x000a0;12) <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0070" ref-type="bibr">[14]</xref>, <xref rid="b0075" ref-type="bibr">[15]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0090" ref-type="bibr">[18]</xref>, <xref rid="b0125" ref-type="bibr">[25]</xref>, <xref rid="b0145" ref-type="bibr">[29]</xref>, <xref rid="b0155" ref-type="bibr">[31]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>, <xref rid="b0180" ref-type="bibr">[36]</xref>, homogeneity index (n&#x000a0;=&#x000a0;4) <xref rid="b0070" ref-type="bibr">[14]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0120" ref-type="bibr">[24]</xref>, <xref rid="b0155" ref-type="bibr">[31]</xref> and conformity index (n&#x000a0;=&#x000a0;2) <xref rid="b0070" ref-type="bibr">[14]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>. Details of the outcome measurements are shown in <xref rid="t0005" ref-type="table">Table 1</xref>.</p></sec></sec><sec id="s0075"><title>Risk of bias assessment</title><p id="p0110">Of the 26 included studies, the overall risk of bias of 15 studies (57.7&#x000a0;%) were considered as low <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0075" ref-type="bibr">[15]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0115" ref-type="bibr">[23]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0145" ref-type="bibr">[29]</xref>, <xref rid="b0150" ref-type="bibr">[30]</xref>, <xref rid="b0160" ref-type="bibr">[32]</xref> and 11 (42.3&#x000a0;%) as moderate <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0070" ref-type="bibr">[14]</xref>, <xref rid="b0090" ref-type="bibr">[18]</xref>, <xref rid="b0120" ref-type="bibr">[24]</xref>, <xref rid="b0125" ref-type="bibr">[25]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref>, <xref rid="b0155" ref-type="bibr">[31]</xref>, <xref rid="b0165" ref-type="bibr">[33]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>, <xref rid="b0180" ref-type="bibr">[36]</xref> (<xref rid="s0120" ref-type="sec">Supplementary Table 1</xref>). All the included studies had a low risk of bias in the two domains: i) bias in classification of intervention and ii) bias due to deviations from intended interventions. However, 4 studies (15.4&#x000a0;%) had a moderate risk of bias in each of the domains of outcome measurement <xref rid="b0070" ref-type="bibr">[14]</xref>, <xref rid="b0125" ref-type="bibr">[25]</xref>, <xref rid="b0155" ref-type="bibr">[31]</xref>, <xref rid="b0180" ref-type="bibr">[36]</xref> and selection of reported results <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0120" ref-type="bibr">[24]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref>, <xref rid="b0165" ref-type="bibr">[33]</xref>. Three studies (11.5&#x000a0;%) had a moderate risk of bias due to missing data <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0090" ref-type="bibr">[18]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref>.</p></sec><sec id="s0080"><title>Results of meta-analyses</title><p id="p0115">Regarding outcomes analysis, the 1-year, 2-year, 3-year or 5-year survival outcomes of OS, PFS and LC were either reported or estimated based on the Kaplan-Meier curve in 10 included studies <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref>, <xref rid="b0165" ref-type="bibr">[33]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>.</p><p id="p0120">Of the 18 studies reporting toxicity, only 16 were included in this meta-analysis with extractable data. The toxicities reported in these studies were graded using different versions of Common Terminology Criteria for Adverse Events (version 4.0 [n&#x000a0;=&#x000a0;4] <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, version 4.03 [n&#x000a0;=&#x000a0;6] <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref>, <xref rid="b0165" ref-type="bibr">[33]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref>, version 5.0 [n&#x000a0;=&#x000a0;3] <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0145" ref-type="bibr">[29]</xref>, version 4.0 and 5.0 [n&#x000a0;=&#x000a0;1] <xref rid="b0095" ref-type="bibr">[19]</xref>; total&#x000a0;=&#x000a0;14 studies). RTOG toxicity grading was used in 1 study <xref rid="b0175" ref-type="bibr">[35]</xref>, while 1 did not report the grading system <xref rid="b0080" ref-type="bibr">[16]</xref>.</p><sec id="s0085"><title>Primary NPC</title><p id="p0125">The pooled 1-year OS was 96&#x000a0;% (95&#x000a0;% CI&#x000a0;=&#x000a0;92&#x000a0;%-98&#x000a0;%) with low heterogeneity (<italic>I</italic><sup>2</sup>&#x000a0;=&#x000a0;2&#x000a0;%) among 287 primary NPC patients receiving PBT or CIBT in 6 studies <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref> (<xref rid="f0010" ref-type="fig">Fig. 2</xref>A). Based on the data of 327 patients in 7 studies <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>, the pooled 2-year OS was 93&#x000a0;% (95&#x000a0;% CI&#x000a0;=&#x000a0;83&#x000a0;%-97&#x000a0;%) with substantial heterogeneity (<italic>I</italic><sup>2</sup>&#x000a0;=&#x000a0;62&#x000a0;%) (<xref rid="f0010" ref-type="fig">Fig. 2</xref>B). The pooled 3-year and 5-year OS were 90&#x000a0;% (95&#x000a0;% CI&#x000a0;=&#x000a0;73&#x000a0;%-97&#x000a0;%, <italic>I</italic><sup>2</sup>&#x000a0;=&#x000a0;80&#x000a0;%, 4 studies, n&#x000a0;=&#x000a0;181) <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref> and 73&#x000a0;% (95&#x000a0;% CI&#x000a0;=&#x000a0;52&#x000a0;%-87&#x000a0;%, <italic>I</italic><sup>2</sup>&#x000a0;=&#x000a0;56&#x000a0;%, 3 studies, n&#x000a0;=&#x000a0;98) <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref> respectively (<xref rid="f0010" ref-type="fig">Fig. 2</xref>C to 2D) (<xref rid="t0010" ref-type="table">Table 2</xref>, <xref rid="s0120" ref-type="sec">Supplementary Table 2</xref>). By excluding studies with patients having nasopharyngeal papillary adenocarcinoma, and salivary gland-type carcinomas of the nasopharynx, the sensitivity analyses showed that the pooled 1-year, 2-year and 3-year OS were 98&#x000a0;% (95&#x000a0;% CI&#x000a0;=&#x000a0;95&#x000a0;%-99&#x000a0;%, <italic>I</italic><sup>2</sup>&#x000a0;=&#x000a0;0&#x000a0;%), 94&#x000a0;% (95&#x000a0;% CI&#x000a0;=&#x000a0;84&#x000a0;%-98&#x000a0;%, <italic>I</italic><sup>2</sup>&#x000a0;=&#x000a0;68&#x000a0;%) and 94&#x000a0;% (95&#x000a0;% CI&#x000a0;=&#x000a0;88&#x000a0;%-97&#x000a0;%, <italic>I</italic><sup>2</sup>&#x000a0;=&#x000a0;0&#x000a0;%) (<xref rid="t0010" ref-type="table">Table 2</xref>). The study by Akbaba et al. <xref rid="b0135" ref-type="bibr">[27]</xref> reported that the estimated 5-year OS was 86&#x000a0;% for patients treated with a mixed beam approach. The subgroup analyses showed that there was no significant difference between patients receiving PBT and a mixed beam approach in the pooled 2-year OS (<italic>p</italic>&#x000a0;=&#x000a0;0.92) and 3-year OS (<italic>p</italic>&#x000a0;=&#x000a0;0.18) (<xref rid="s0120" ref-type="sec">Supplementary Fig. 1</xref>A to 1B).<fig id="f0010"><label>Fig. 2</label><caption><p>Random-effects meta-analysis of overall survival (OS) rates among Primary NPC patients: a)1-year rate; b) 2-year rate; c) 3-year rate; and d) 5-year rate.</p></caption><graphic xlink:href="gr2"/></fig><table-wrap position="float" id="t0010"><label>Table 2</label><caption><p>Survival outcome random-effects meta-analysis summary table.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Topic</th><th rowspan="2">No. of studies</th><th rowspan="2">Total patients</th><th rowspan="2">Median follow-up range (Median) (months)</th><th rowspan="2">No. (%) of T3/T4 disease patients</th><th>Heterogeneity test</th><th rowspan="2">Outcome (95&#x000a0;% confidence interval)</th></tr><tr><th><italic>I<sup>2</sup></italic></th></tr></thead><tbody><tr><td colspan="7">Meta-analysis for primary NPC patients</td></tr><tr><td>&#x000a0;1-year OS rates</td><td>6</td><td>287</td><td>19&#x02013;40 (28.5)</td><td>N/A <italic><sup>a</sup></italic></td><td>2&#x000a0;%</td><td>96&#x000a0;% (92&#x000a0;%-98&#x000a0;%)</td></tr><tr><td>&#x000a0;2-year OS rates</td><td>7</td><td>327</td><td>19&#x02013;40 (25)</td><td>N/A <italic><sup>a</sup></italic></td><td>62&#x000a0;%</td><td>93&#x000a0;% (83&#x000a0;%-97&#x000a0;%)</td></tr><tr><td>&#x000a0;3-year OS rates</td><td>4</td><td>181</td><td>19&#x02013;40 (32)</td><td>N/A <italic><sup>a</sup></italic></td><td>80&#x000a0;%</td><td>90&#x000a0;% (73&#x000a0;%-97&#x000a0;%)</td></tr><tr><td>&#x000a0;5-year OS rates</td><td>3</td><td>98</td><td>19&#x02013;40 (32)</td><td>N/A <italic><sup>a</sup></italic></td><td>56&#x000a0;%</td><td>73&#x000a0;% (52&#x000a0;%-87&#x000a0;%)</td></tr><tr><td>&#x000a0;1-year PFS rates</td><td>3</td><td>143</td><td>14&#x02013;24 (19)</td><td>N/A <italic><sup>a</sup></italic></td><td>63&#x000a0;%</td><td>94&#x000a0;% (83&#x000a0;%-98&#x000a0;%)</td></tr><tr><td>&#x000a0;2-year PFS rates</td><td>3</td><td>135</td><td>19&#x02013;25 (24)</td><td>40 (30&#x000a0;%)/41 (30&#x000a0;%)</td><td>73&#x000a0;%</td><td>91&#x000a0;% (75&#x000a0;%-97&#x000a0;%)</td></tr><tr><td>&#x000a0;1-year LC rates</td><td>3</td><td>153</td><td>32&#x02013;40 (32)</td><td>N/A <italic><sup>a</sup></italic></td><td>56&#x000a0;%</td><td>96&#x000a0;% (83&#x000a0;%-99&#x000a0;%)</td></tr><tr><td>&#x000a0;2-year LC rates</td><td>5</td><td>220</td><td>24&#x02013;40 (32)</td><td>N/A <italic><sup>a</sup></italic></td><td>56&#x000a0;%</td><td>91&#x000a0;% (82&#x000a0;%-96&#x000a0;%)</td></tr><tr><td>&#x000a0;3-year LC rates</td><td>3</td><td>153</td><td>32&#x02013;40 (32)</td><td>N/A <italic><sup>a</sup></italic></td><td>86&#x000a0;%</td><td>89&#x000a0;% (64&#x000a0;%-98&#x000a0;%)</td></tr><tr><td>&#x000a0;5-year LC rates</td><td>2</td><td>84</td><td>32&#x02013;40 (36)</td><td>N/A <italic><sup>a</sup></italic></td><td>90&#x000a0;%</td><td>75&#x000a0;% (21&#x000a0;%-97&#x000a0;%)</td></tr><tr><td colspan="7">Sensitivity analysis on OS rates by excluding studies with patients having nasopharyngeal papillary adenocarcinoma, and salivary gland-type carcinomas of the nasopharynx</td></tr><tr><td>&#x000a0;1-year OS rates</td><td>5</td><td>228</td><td>19&#x02013;40 (25)</td><td>N/A <italic><sup>a</sup></italic></td><td>0&#x000a0;%</td><td>98&#x000a0;% (95&#x000a0;%-99&#x000a0;%)</td></tr><tr><td>&#x000a0;2-year OS rates</td><td>6</td><td>268</td><td>19&#x02013;40 (24.5)</td><td>N/A <italic><sup>a</sup></italic></td><td>68&#x000a0;%</td><td>94&#x000a0;% (84&#x000a0;%-98&#x000a0;%)</td></tr><tr><td>&#x000a0;3-year OS rates</td><td>3</td><td>122</td><td>19&#x02013;40 (32)</td><td>N/A <italic><sup>a</sup></italic></td><td>0&#x000a0;%</td><td>94&#x000a0;% (88&#x000a0;%-97&#x000a0;%)</td></tr></tbody></table><table-wrap-foot><fn id="sp0060"><p>Note: <sup>a</sup>Unable to extract data from some studies.</p></fn><fn id="sp0065"><p>Abbreviations: LC, local control; N/A, not applicable; OS, overall survival; PFS, progression-free survival.</p></fn></table-wrap-foot></table-wrap></p><p id="p0130">Furthermore, from the data of 143 patients in 3 studies <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0165" ref-type="bibr">[33]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref>, the pooled 1-year PFS was 94&#x000a0;% (95&#x000a0;% CI&#x000a0;=&#x000a0;83&#x000a0;%-98&#x000a0;%) with substantial heterogeneity (<italic>I<sup>2</sup></italic>&#x000a0;=&#x000a0;63&#x000a0;%). The pooled 2-year PFS was 91&#x000a0;% (95&#x000a0;% CI&#x000a0;=&#x000a0;75&#x000a0;%-97&#x000a0;%) with substantial heterogeneity (<italic>I<sup>2</sup></italic>&#x000a0;=&#x000a0;73&#x000a0;%) among 135 patients from 3 studies <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref> (<xref rid="t0010" ref-type="table">Table 2</xref>, <xref rid="s0120" ref-type="sec">Supplementary Table 2</xref>). The study by Hu et al. <xref rid="b0110" ref-type="bibr">[22]</xref> demonstrated a 3-year PFS of 85&#x000a0;% for patients receiving a mixed beam approach.</p><p id="p0135">The pooled 1-year LC was 96&#x000a0;% (95&#x000a0;% CI&#x000a0;=&#x000a0;83&#x000a0;%-99&#x000a0;%) with moderate heterogeneity (<italic>I<sup>2</sup></italic>&#x000a0;=&#x000a0;56&#x000a0;%) in 153 patients from 3 studies <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>. The pooled 2-year LC was 91&#x000a0;% (95&#x000a0;% CI&#x000a0;=&#x000a0;82&#x000a0;%-96&#x000a0;%) with moderate heterogeneity (<italic>I<sup>2</sup></italic>&#x000a0;=&#x000a0;56&#x000a0;%) among 220 patients in 5 studies <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>. Besides, the pooled 3-year and 5-year LC were 89&#x000a0;% (95&#x000a0;% CI&#x000a0;=&#x000a0;64&#x000a0;%-98&#x000a0;%, <italic>I</italic><sup>2</sup>&#x000a0;=&#x000a0;86&#x000a0;%, 3 studies, n&#x000a0;=&#x000a0;153) <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref> and 75&#x000a0;% (95&#x000a0;% CI&#x000a0;=&#x000a0;21&#x000a0;%-97&#x000a0;%, <italic>I</italic><sup>2</sup>&#x000a0;=&#x000a0;90&#x000a0;%, 2 studies, n&#x000a0;=&#x000a0;84) <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref> respectively (<xref rid="t0010" ref-type="table">Table 2</xref>, <xref rid="s0120" ref-type="sec">Supplementary Table 2</xref>). Since the proportion of T3 and T4 NPC patients included in these studies could significantly affect the local control rates, we estimated the T3 and T4 distribution based on the extractable data (excluding the studies by Akbaba et al. and Ji&#x00159;&#x000ed; et al. <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>). The distribution for T3 and T4 disease were 27&#x000a0;% and 47&#x000a0;% for both 1-year and 3-year LC rates <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, 30&#x000a0;% and 48&#x000a0;% for 2-year LC rate <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref>, as well as 6&#x000a0;% and 57&#x000a0;% for 5-year LC rate <xref rid="b0130" ref-type="bibr">[26]</xref>.</p><p id="p0140">Toxicities that may occur due to particle beam therapy among NPC patients were also examined. After analyzing the data of 346 patients in 9 studies <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0165" ref-type="bibr">[33]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref>, the pooled proportion of patients who developed grade &#x02265;3 (&#x02265;G3) dermatitis was 12&#x000a0;% (95&#x000a0;% CI&#x000a0;=&#x000a0;5&#x000a0;%-26&#x000a0;%). Considerable heterogeneity was found between studies (<italic>I<sup>2</sup></italic>&#x000a0;=&#x000a0;81&#x000a0;%) (<xref rid="t0015" ref-type="table">Table 3</xref>, <xref rid="s0120" ref-type="sec">Supplementary Table 3</xref>).<table-wrap position="float" id="t0015"><label>Table 3</label><caption><p>Safety outcome random-effects meta-analysis summary table.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Toxicity</th><th rowspan="2">No. of studies</th><th rowspan="2">Total patients</th><th rowspan="2">Median follow-up range (Median) (months)</th><th rowspan="2">No. (%) of T3/T4 disease patients</th><th>Heterogeneity test</th><th rowspan="2">Proportion (95&#x000a0;% confidence interval)</th></tr><tr><th><italic>I<sup>2</sup></italic></th></tr></thead><tbody><tr><td>Primary NPC patients</td><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x000a0;Grade&#x000a0;&#x02265;&#x000a0;3 dermatitis</td><td>9</td><td>346</td><td>14&#x02013;69 (25)</td><td>N/A <italic><sup>a</sup></italic></td><td>81&#x000a0;%</td><td>12&#x000a0;% (5&#x000a0;%-26&#x000a0;%)</td></tr><tr><td>&#x000a0;Grade 2 mucositis</td><td>9</td><td>326</td><td>14&#x02013;69 (25)</td><td>N/A <italic><sup>a</sup></italic></td><td>50&#x000a0;%</td><td>42&#x000a0;% (34&#x000a0;%-50&#x000a0;%)</td></tr><tr><td>&#x000a0;Grade&#x000a0;&#x02265;&#x000a0;3 mucositis</td><td>10</td><td>406</td><td>14&#x02013;69 (25)</td><td>N/A <italic><sup>a</sup></italic></td><td>71&#x000a0;%</td><td>11&#x000a0;% (6&#x000a0;%-19&#x000a0;%)</td></tr><tr><td>&#x000a0;Grade 2 xerostomia</td><td>9</td><td>308</td><td>19&#x02013;69 (32)</td><td>N/A <italic><sup>a</sup></italic></td><td>72&#x000a0;%</td><td>22&#x000a0;% (13&#x000a0;%-36&#x000a0;%)</td></tr><tr><td>&#x000a0;Grade&#x000a0;&#x02265;&#x000a0;3 xerostomia</td><td>8</td><td>281</td><td>19&#x02013;69 (32)</td><td>N/A <italic><sup>a</sup></italic></td><td>0&#x000a0;%</td><td>2&#x000a0;% (1&#x000a0;%-4%)</td></tr><tr><td>&#x000a0;Grade&#x000a0;&#x02265;&#x000a0;3 late toxicity</td><td>5</td><td>167</td><td>22&#x02013;90 (32)</td><td>N/A <italic><sup>a</sup></italic></td><td>70&#x000a0;%</td><td>15&#x000a0;% (5&#x000a0;%-35&#x000a0;%)</td></tr><tr><td>&#x000a0;Nasogastric/Gastrostomy tube required</td><td>10</td><td>331</td><td>14&#x02013;69 (25)</td><td>N/A <italic><sup>a</sup></italic></td><td>84&#x000a0;%</td><td>13&#x000a0;% (5&#x000a0;%-31&#x000a0;%)</td></tr></tbody></table><table-wrap-foot><fn><p>Note: <sup>a</sup>Unable to extract data from some studies.</p></fn></table-wrap-foot></table-wrap></p><p id="p0145">According to the data of 406 patients in 10 studies <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref>, <xref rid="b0165" ref-type="bibr">[33]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>, the pooled rate of experiencing &#x02265;G3 mucositis was 11&#x000a0;% (95&#x000a0;% CI&#x000a0;=&#x000a0;6&#x000a0;%-19&#x000a0;%) with substantial heterogeneity (<italic>I<sup>2</sup></italic>&#x000a0;=&#x000a0;71&#x000a0;%). Furthermore, from the data of 326 patients in 9 studies <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref>, <xref rid="b0165" ref-type="bibr">[33]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>, where 72&#x000a0;% received concurrent/concomitant chemotherapy, the pooled rate of developing grade 2 (G2) mucositis was 42&#x000a0;% (95&#x000a0;% CI&#x000a0;=&#x000a0;34&#x000a0;%-50&#x000a0;%) with moderate heterogeneity (<italic>I<sup>2</sup></italic>&#x000a0;=&#x000a0;50&#x000a0;%) (<xref rid="t0015" ref-type="table">Table 3</xref>, <xref rid="s0120" ref-type="sec">Supplementary Table 3</xref>).</p><p id="p0150">For the development of G2 xerostomia, the data of 308 patients from 9 studies <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref> showed a pooled rate of 22&#x000a0;% (95&#x000a0;% CI&#x000a0;=&#x000a0;13&#x000a0;%-36&#x000a0;%) with substantial heterogeneity found (<italic>I<sup>2</sup></italic>&#x000a0;=&#x000a0;72&#x000a0;%). However, based on the data of 281 patients from 8 studies <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>, the pooled rate of &#x02265;G3 xerostomia was only 2&#x000a0;% (95&#x000a0;% CI&#x000a0;=&#x000a0;1&#x000a0;%-4%). The heterogeneity between studies was low (<italic>I<sup>2</sup></italic>&#x000a0;=&#x000a0;0&#x000a0;%) (<xref rid="t0015" ref-type="table">Table 3</xref>, <xref rid="s0120" ref-type="sec">Supplementary Table 3</xref>).</p><p id="p0155">After analyzing the data of 167 patients in 5 studies <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>, the pooled occurrence rate of any &#x02265;G3 late toxicity was 15&#x000a0;% (95&#x000a0;% CI&#x000a0;=&#x000a0;5&#x000a0;%-35&#x000a0;%), where there was substantial heterogeneity between studies (<italic>I<sup>2</sup></italic>&#x000a0;=&#x000a0;70&#x000a0;%) (<xref rid="t0015" ref-type="table">Table 3</xref>, <xref rid="s0120" ref-type="sec">Supplementary Table 3</xref>). There were various types of &#x02265;G3 late toxicity, with the most being hearing loss with 4 out of 167 patients (2&#x000a0;%) <xref rid="b0065" ref-type="bibr">[13]</xref>. Others included aspiration pneumonia (n&#x000a0;=&#x000a0;2) <xref rid="b0065" ref-type="bibr">[13]</xref>, lockjaw (n&#x000a0;=&#x000a0;1), hypopituitarism (n&#x000a0;=&#x000a0;1), osteoradionecrosis (n&#x000a0;=&#x000a0;1), tympanic effusion (n&#x000a0;=&#x000a0;1), cranial nerve deficit (n&#x000a0;=&#x000a0;1) and affected temporal lobe (n&#x000a0;=&#x000a0;1) <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>. However, details were not reported in 8 cases of &#x02265;G3 late toxicity <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>.</p><p id="p0160">Furthermore, 10 studies with a total of 331 patients were analyzed for nasogastric/gastrostomy tube placement during or after treatment <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref>, <xref rid="b0165" ref-type="bibr">[33]</xref>, <xref rid="b0170" ref-type="bibr">[34]</xref>. The pooled rate for tube placement was 13&#x000a0;% (95&#x000a0;% CI&#x000a0;=&#x000a0;5&#x000a0;%-31&#x000a0;%), with substantial heterogeneity between studies (<italic>I<sup>2</sup></italic>&#x000a0;=&#x000a0;84&#x000a0;%) (<xref rid="t0015" ref-type="table">Table 3</xref>, <xref rid="s0120" ref-type="sec">Supplementary Table 3</xref>). It is noteworthy that the studies by Uezono et al. and Williams et al. had a particularly high rate of tube placement (59&#x000a0;% [95&#x000a0;% CI&#x000a0;=&#x000a0;33&#x000a0;%-82&#x000a0;%] and 62&#x000a0;% [95&#x000a0;% CI&#x000a0;=&#x000a0;41&#x000a0;%-80&#x000a0;%], respectively) <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, when compared with the rest of the studies (<xref rid="s0120" ref-type="sec">Supplementary Table 3</xref>).</p></sec><sec id="s0090"><title>Locally recurrent NPC</title><p id="p0165">Four studies evaluated the survival outcomes and toxicity among 339 locally recurrent NPC patients <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0115" ref-type="bibr">[23]</xref>, <xref rid="b0145" ref-type="bibr">[29]</xref>. Details are shown in <xref rid="t0005" ref-type="table">Table 1</xref>. Since studies by Hu et al. <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0115" ref-type="bibr">[23]</xref> recruited patients from the same center in China with a similar follow-up period, performing a meta-analysis for these studies might introduce potential bias. Therefore, only the study with the largest sample size and longest follow-up period by Hu et al. <xref rid="b0105" ref-type="bibr">[21]</xref> was selected and the results were presented qualitatively <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0145" ref-type="bibr">[29]</xref>.</p><p id="p0170">Hu et al. <xref rid="b0105" ref-type="bibr">[21]</xref> reported the outcomes of CIBT for 206 locally recurrent NPC patients in China. At a median follow-up period of 23&#x000a0;months, the 2-year OS, LC and regional control rates were 84&#x000a0;%, 58&#x000a0;%, and 87&#x000a0;%, respectively. The estimated 1-year OS, LC and regional control rates based on the Kaplan-Meier curve were 92&#x000a0;%, 88&#x000a0;% and 96&#x000a0;%.</p><p id="p0175">Another study by Dionisi et al. <xref rid="b0145" ref-type="bibr">[29]</xref> assessed 17 recurrent NPC patients who received PBT in Italy with a median follow-up period of 10&#x000a0;months. The OS and LC rates at 18&#x000a0;months were 54&#x000a0;% and 67&#x000a0;%, respectively. The estimated 1-year OS and LC rates based on the Kaplan-Meier curve were 65&#x000a0;% and 80&#x000a0;%.</p><p id="p0180">Regarding late toxicity, Hu et al. <xref rid="b0105" ref-type="bibr">[21]</xref> showed that 15 out of 206 patients (7&#x000a0;%) had&#x000a0;&#x02264;&#x000a0;G2 late xerostomia. In the studies by Hu et al. and Dionisi et al. <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0145" ref-type="bibr">[29]</xref>, 45 out of 223 locally recurrent NPC patients (20&#x000a0;%) developed &#x02265;G3 late toxicity. The most common type of &#x02265;G3 late toxicity was nasopharyngeal necrosis with 33 cases, followed by hearing impairment (n&#x000a0;=&#x000a0;6), temporal lobe necrosis (n&#x000a0;=&#x000a0;2), xerostomia (n&#x000a0;=&#x000a0;1), dysphagia (n&#x000a0;=&#x000a0;1), cranial neuropathy (n&#x000a0;=&#x000a0;1) and carotid blowout (n&#x000a0;=&#x000a0;1). Amongst these 45 patients, there were 17 with bleeding complications, and 11 patients succumbed. This yielded a mortality rate of approximately 5&#x000a0;% from the 223 locally recurrent NPC patients <xref rid="b0105" ref-type="bibr">[21]</xref>, <xref rid="b0145" ref-type="bibr">[29]</xref>.</p></sec></sec><sec id="s0095"><title>Comparing PBT versus IMRT</title><p id="p0185">Four individual studies made comparisons between the outcomes of PBT with IMRT. Two found that PBT showed better survival and toxicity results than IMRT <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref>.</p><p id="p0190">In the study by Alterio et al. <xref rid="b0140" ref-type="bibr">[28]</xref>, a mixed beam approach of IMRT and PBT performed better among primary NPC patients than IMRT alone, with a 2-year PFS rate of 76&#x000a0;% versus 69&#x000a0;%, local PFS rate of 96&#x000a0;% versus 89&#x000a0;%, and LC rate of 96&#x000a0;% versus 81&#x000a0;%. In addition, patients treated using the mixed beam approach were less likely to develop &#x02265;G3 mucositis (11&#x000a0;%) and G2 xerostomia (7&#x000a0;%), when compared with IMRT (&#x02265;G3 mucositis: 76&#x000a0;% and G2 xerostomia:35&#x000a0;%).</p><p id="p0195">Li et al. <xref rid="b0095" ref-type="bibr">[19]</xref> compared the two treatment modality groups, where 71&#x000a0;% of the patients receiving PBT had stage III-IVa, while the control group consisted of 67&#x000a0;% stage III-IVa patients. The intervention and control groups had 89&#x000a0;% and 94&#x000a0;% of patients treated with chemoradiotherapy. The results showed that PBT led to better outcomes than IMRT, with 3-year OS of 100&#x000a0;% versus 94&#x000a0;%, 2-year PFS of 96&#x000a0;% versus 77&#x000a0;%, and 2-year locoregional failure-free survival of 100&#x000a0;% versus 86&#x000a0;%. Moreover, patients receiving PBT were less likely to develop &#x02265;G3 mucositis (4&#x000a0;%) and &#x02265;G3 xerostomia (0&#x000a0;%) when compared to IMRT (&#x02265;G3 mucositis: 10&#x000a0;% and &#x02265;G3 xerostomia: 22&#x000a0;%). However, patients reported a lower rate of &#x02265;G3 dermatitis with IMRT than PBT (2&#x000a0;% versus 4&#x000a0;%).</p><p id="p0200">For the remaining 2 studies, only toxicity assessment was performed. The study by Sanford et al. showed that when comparing &#x02265;G3 late toxicity among primary NPC patients, PBT (13&#x000a0;%) performed better than IMRT (17&#x000a0;%) <xref rid="b0065" ref-type="bibr">[13]</xref>. On the contrary, Holliday et al. <xref rid="b0060" ref-type="bibr">[12]</xref> found that IMRT might perform better. Primary NPC patients were less likely to develop &#x02265;G3 dermatitis (25&#x000a0;%) and &#x02265;G3 late toxicity (15&#x000a0;%) with IMRT when compared with PBT (&#x02265;G3 dermatitis: 40&#x000a0;%, <italic>p</italic>&#x000a0;=&#x000a0;0.412; &#x02265;G3 late toxicity: 50&#x000a0;%, <italic>p</italic>&#x000a0;=&#x000a0;0.542). However, there was no statistical difference in such comparisons. The sample size (PBT [n&#x000a0;=&#x000a0;10] and IMRT [n&#x000a0;=&#x000a0;20]) and differences in systemic therapy administration between modalities (PBT [80&#x000a0;% induction chemotherapy/100&#x000a0;% concurrent chemotherapy] and IMRT [75&#x000a0;% induction chemotherapy/90&#x000a0;% concurrent chemotherapy]) should be taken into consideration when comparing the toxicity rates of this study.</p></sec><sec id="s0100"><title>Dosimetric evaluation of particle beam therapy</title><p id="p0205">Of these 26 included studies, six examined dosimetric parameters <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0145" ref-type="bibr">[29]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>. These parameters included the planning target volume and doses to the OARs such as the spinal cord, brain, parotids, optic chiasm, and cochlea. Apart from the study by Sanford et al., which only showed several individual cases <xref rid="b0065" ref-type="bibr">[13]</xref>, the other papers provided analyzable dosimetric parameters of median doses to OARs <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0145" ref-type="bibr">[29]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>.</p><p id="p0210">Based on the 4 studies that compared the dosimetric parameters of the PBT/CIBT with IMRT <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0125" ref-type="bibr">[25]</xref>, <xref rid="b0155" ref-type="bibr">[31]</xref>, <xref rid="b0180" ref-type="bibr">[36]</xref>, it was observed that the doses of OARs by PBT/CIBT were less than IMRT. The implication is that with fewer doses of OARs, the RT-related adverse effects on patients would be reduced.</p><p id="p0215">When examining the dose to the parotid for node-negative neck, Williams et al. <xref rid="b0085" ref-type="bibr">[17]</xref> reported that the median of the mean dose to the parotid was 23.22&#x000a0;Gy (RBE). The study by Ji&#x00159;&#x000ed; et al. showed that 93&#x000a0;% of the patients were node-positive; the median of the mean dose to the left and right parotid was 45.76 GyE and 28.86 GyE, respectively <xref rid="b0175" ref-type="bibr">[35]</xref>. A high parotid dose was also observed by Uezono et al. on 17 node-positive pediatric and adolescent NPC; the median of the mean dose to the ipsilateral and contralateral parotid gland were 53.5&#x000a0;Gy (RBE) and 42.4&#x000a0;Gy (RBE), respectively <xref rid="b0080" ref-type="bibr">[16]</xref>. Doses to the other OARs were generally within their respective dose constraints. The median of the mean brain dose was 6.53&#x000a0;Gy (RBE), 3.36 GyE, and 7.9&#x000a0;Gy (RBE) for Holliday et al., Ji&#x00159;&#x000ed; et al., and Uezono et al., respectively <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0175" ref-type="bibr">[35]</xref>. For the maximum dose to the spinal cord at 2&#x000a0;% of volume, the median dose in Ji&#x00159;&#x000ed; et al. was 19.63 GyE <xref rid="b0175" ref-type="bibr">[35]</xref>, while in Williams et al., the median of the maximum spinal cord and optic chiasm doses were 37.04&#x000a0;Gy (RBE) and 41.72&#x000a0;Gy (RBE), respectively <xref rid="b0085" ref-type="bibr">[17]</xref>. Moreover, when investigating the mean cochlea dose, the median of ipsilateral and contralateral cochlea for Ji&#x00159;&#x000ed; et al. were 39.25 GyE and 25.07 GyE, respectively <xref rid="b0175" ref-type="bibr">[35]</xref>. For Uezono et al., the median of the mean dose to the ipsilateral and contralateral cochlea were 53.7&#x000a0;Gy (RBE) and 33.4&#x000a0;Gy (RBE), respectively <xref rid="b0080" ref-type="bibr">[16]</xref>.</p><p id="p0220">Of note, the study by Holliday et al. was the only study comparing PBT and IMRT with a correlation of toxicities and dosimetric parameters to the OARs <xref rid="b0060" ref-type="bibr">[12]</xref>. As in other studies, they demonstrated that PBT had better dose sparing to OARs. The median of the mean dose to the oral cavity was 17.3&#x000a0;Gy (RBE) and 40.6&#x000a0;Gy for PBT and IMRT, respectively (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001), while that for the brainstem was 26.7&#x000a0;Gy (RBE) and 34.2&#x000a0;Gy, respectively (<italic>P</italic>&#x000a0;=&#x000a0;0.002). PBT had a median of the mean whole-brain dose at 6.53&#x000a0;Gy (RBE), while IMRT was 10.94&#x000a0;Gy (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001). For the mean mandible dose, the median for PBT was 32.62&#x000a0;Gy (RBE), while the median for IMRT was 42.65&#x000a0;Gy (<italic>P</italic>&#x000a0;=&#x000a0;0.020). More importantly, it was found that patients treated with PBT were 45&#x000a0;% less likely to receive gastrostomy tube placement compared with IMRT patients (<italic>P</italic>&#x000a0;=&#x000a0;0.020), presumably due to a decreased dose to the oral cavity.</p></sec></sec><sec id="s0105"><title>Discussion</title><p id="p0225">In this systematic review, most of the included studies were published between 2019 and 2021. They were mainly conducted in the US and China. The most common modality in particle beam therapy for NPC was PBT, followed by CIBT and a mixed beam approach incorporating photon-based IMRT. Our results showed excellent short-term treatment outcomes: (1) The pooled OS at 1-year, 2-year and 3-year for primary NPC patients who received particle beam therapy were 96&#x000a0;%, 93&#x000a0;% and 90&#x000a0;%, respectively; (2) The pooled 1-year and 2-year PFS, and LC for these patients were above 90&#x000a0;%; (3) For locally recurrent NPC patients, the 1-year OS rate ranged from 65&#x000a0;% to 92&#x000a0;% while 1-year LC rate ranged from 80&#x000a0;% to 88&#x000a0;%; (4) Notably, both PBT and CIBT were safe in general among primary and recurrent patients, with &#x02265;G3 late toxicity rates of 20&#x000a0;% or less. An approximately 5&#x000a0;% mortality rate was reported among recurrent patients.</p><p id="p0230">Furthermore, in the studies that reported dosimetry, 3 out of the 4 studies <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref> found that PBT achieved better OAR dose sparing than IMRT without affecting tumor coverage. It is reasonable to speculate that this would translate into fewer RT-related complications. This observation was demonstrated in the study by Holliday et al., which showed that significantly fewer patients required gastrostomy tube placement with PBT compared with IMRT due to a decrease in mean oral cavity dose <xref rid="b0060" ref-type="bibr">[12]</xref>. Moreover, substantial lower doses to brainstem, whole brain, and mandible were reported, which were desirable advantages based on the As Low As Reasonably Practicable principle. Nonetheless, it is noteworthy that different proton beam arrangement may influence the resultant dose distribution. Further research should be conducted to verify these observations.</p><p id="p0235">Given these very promising early results and dosimetric benefits, the National Comprehensive Cancer Network had made a recommendation to consider PBT for NPC when normal tissue constraints could not be met by photon-based IMRT <xref rid="b0185" ref-type="bibr">[37]</xref>. Furthermore, the findings of our study suggested that CIBT should be at least equally safe and effective in improving outcomes for both primary and locally recurrent NPC. As shown in <xref rid="s0120" ref-type="sec">Supplementary Table 2</xref>, the efficacy of CIBT alone or CIBT/IMRT mixed beam approach was more or less similar to that of PBT alone or PBT/IMRT mixed beam approach. And in some cases, it could be an even better alternative to PBT, given its excellent conformal dose distribution and improved biological effectiveness over photon <xref rid="b0110" ref-type="bibr">[22]</xref>, <xref rid="b0190" ref-type="bibr">[38]</xref>. This was speculated by a better 1-year OS rate in studies using CIBT for locally recurrent NPC patients (<xref rid="s0120" ref-type="sec">Supplementary Table 2</xref>). However, confirmatory study is required given the limitations of cross studies comparison between two institutions.</p><p id="p0240">In addition, patients&#x02019; preferences also played a significant role in informing healthcare decisions. Being cured and surviving were both of the highest priorities compared to other functional endpoints among head and neck cancer patients <xref rid="b0195" ref-type="bibr">[39]</xref>. Studies have suggested that most head and neck cancer patients were unwilling to compromise survival outcomes with reduced treatment toxicity. This suggested that NPC cancer patients might also prioritize survival over the quality of life <xref rid="b0200" ref-type="bibr">[40]</xref>. Since the results of our systematic review showed that particle beam therapy brought favorable survival outcomes without causing severe toxic effects, when compared with photon-based IMRT <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0140" ref-type="bibr">[28]</xref>, healthcare professionals and patients would preferentially opt for particle beam therapy once this facility is available.</p><p id="p0245">However, the treatment cost of PBT/CIBT is far more expensive than IMRT. Particle beam facilities require high capital investment into building and infrastructure, hardware and software, in addition to maintaining the high operating cost <xref rid="b0205" ref-type="bibr">[41]</xref>. It was reported that the estimated construction cost of a single-vault PBT facility in Canada was CAD$133.62 million, whereas a multi-vault PBT facility could cost up to CAD$321.29 million <xref rid="b0210" ref-type="bibr">[42]</xref>. Therefore, the PBT treatment cost would be much higher than a photon-based IMRT. One study estimated that the cost of intensity-modulated PBT was 3.2&#x02013;4.8 times that of IMRT <xref rid="b0205" ref-type="bibr">[41]</xref>, while a non-modelling study noted that the cost of PBT might be more than triple the cost of IMRT for head and neck cancer <xref rid="b0215" ref-type="bibr">[43]</xref>. Besides, operational costs, cost per fraction, and average time required per fraction should be considered in evaluating the cost-effectiveness of different particle beam therapy for NPC <xref rid="b0215" ref-type="bibr">[43]</xref>. With the ever-increasing costs of cancer management, selecting a cost-effective treatment option for patients is thus imperative. Li et al. recently estimated the cost-effectiveness of PBT on the average NPC patients in China <xref rid="b0205" ref-type="bibr">[41]</xref>. The findings of this study showed that PBT should provide at least a normal tissue complication probability reduction of &#x02265;24&#x000a0;% in long-term dysphagia, xerostomia, and hearing loss in order to be considered cost-effective <xref rid="b0205" ref-type="bibr">[41]</xref>. Only the study by Alterio et al. analysed the cost-effectiveness of the intervention and control treatment <xref rid="b0140" ref-type="bibr">[28]</xref>. Findings from a systematic review suggested that PBT might offer better cost-effectiveness among head and neck cancer patients who were highly vulnerable to acute mucosal toxicities <xref rid="b0220" ref-type="bibr">[44]</xref>. Given the limited study on the cost-effectiveness of particle beam therapy for NPC, future research is eagerly awaited in this aspect. CIBT and additional PBT cost-effectiveness analysis modelling should also be performed using more comprehensive toxicity information. Alternatively, the use of decision support tools, such as the one developed by Tambas et al. <xref rid="b0225" ref-type="bibr">[45]</xref>, may facilitate a quick and effective selection method to identify NPC patients who are most suitable for particle beam therapy.</p><p id="p0250">The strengths of this systematic review are that literature selection, data extraction, and risk of bias assessment were conducted independently by two reviewers. Single-arm random-effect meta-analyses for primary NPC were also performed individually to synthesize the most updated study data on 1-year, 2-year, 3-year and 5-year survival outcomes and toxicity of PBT and CIBT. Details on the use of particle beam therapy among locally recurrent NPC patients were also described qualitatively to ensure the completeness of this review.</p><p id="p0255">However, there are several limitations. The first is the limited patient size. Of all the studies examined, there are only 7 papers with a patient size of 50 or more, which only included 1 with a sample size of more than 100. These small sample sizes can cause misleading estimates due to outliers. The second limitation is the short follow-up time reported in these studies. Because long-term survival outcomes at 5&#x000a0;years or above were grossly lacking, pooled analysis of outcomes could only demonstrate the short-term benefits of the interventions. In particular, the short-term outcome of particle beam therapy should be interpreted with great caution for locally recurrent NPC patients. In fact, the study by Hu et al. on recurrent NPC showed a considerable drop in the 1-year LC rate from 88&#x000a0;% to 2-year LC rate of 58&#x000a0;%, albeit with a reasonable 2-year OS rate of 84&#x000a0;% <xref rid="b0105" ref-type="bibr">[21]</xref>. A similar observation was noted by Dionisi et al., in which the reported 1-year and 1.5-year LC rate was 80&#x000a0;% and 67&#x000a0;%, respectively <xref rid="b0145" ref-type="bibr">[29]</xref>. Future clinical trials should be conducted with an adequate follow-up to investigate long-term outcomes among locally recurrent NPC patients. The third limitation is a lack of standardised reporting on late complications, making the pooling of these datapoints difficult. Furthermore, the heterogeneity of the pooled survival outcomes was moderate or substantial among the studies. This could be attributed to different histological subtypes, small sample sizes, and the use of different modalities of particle beam therapy (i.e., PBT or CIBT alone or a mixed beam approach). Since histological subtypes could potentially influence the treatment outcomes, sensitivity analyses were performed on the primary outcome of OS by excluding patients with nasopharyngeal papillary adenocarcinoma and salivary gland-type carcinomas of the nasopharynx. Both full and sensitivity meta-analyses yielded similar results in the primary outcome of OS, thus supporting the robustness of our findings. We also conducted subgroup analyses on the primary outcome by stratifying studies based on different types of radiotherapy to explore the heterogeneous meta-analysis results (i.e., the pooled 2-year and 3-year OS rate with I<sup>2</sup>&#x000a0;&#x0003e;&#x000a0;50&#x000a0;%). However, there was no significant difference between the subgroups of PBT and the mixed beam approach in the pooled 2-year and 3-year OS. It must also be acknowledged that the treatment planning process for particle beam therapy demands a higher level of quality assurance; for example, particle range uncertainty can lead to dosimetric variations, and this is a pertinent issue in head and neck cancers, when change in body contours due to weight loss during treatment is common. While dosimetric parameters were not available for the majority of the studies, it is at least reassuring that results on survival outcomes and toxicities from this meta-analysis suggest equipoise to IMRT for the treatment of patients with NPC. On this note, treatment outcomes could not be assessed according to the stage of disease and other confounding clinical variables. This limits our interpretations of which groups of patients would benefit most from particle beam therapy. Lastly, there is a lack of randomized controlled trials comparing the effectiveness of PBT or CIBT with photon-based IMRT on survival outcomes and toxicity among NPC patients. This would help to understand the benefits of each modality over each other. More clinical trials in this aspect are needed, and network meta-analyses might be helpful to investigate the comparative effectiveness of different RT modalities for the treatment of NPC in the future.</p></sec><sec id="s0110"><title>Conclusion</title><p id="p0260">This systematic review and meta-analysis showed that primary NPC patients who received PBT or CIBT had excellent short-term results in pooled OS at 1-year, 2-year and 3-year, as well as pooled PFS and LC at 1-year and 2-year. In addition, PBT and CIBT were generally safe in primary and recurrent patients, with &#x02265;G3 late toxicity rates of 20&#x000a0;% or less. Approximately 5&#x000a0;% mortality rate was reported among locally recurrent NPC patients. However, future randomized controlled trials will be needed to compare the long-term effectiveness of PBT or CIBT with photon-based IMRT for NPC. Of note, the ongoing randomized clinical trial NCT04528394 investigating the toxicity and therapeutic efficacy of photon plus CIBT or PBT plus CIBT for newly diagnosed NPC patients will be keenly anticipated. Cost-effectiveness analysis of PBT or CIBT should also be conducted and validated clinically. Findings of these studies would be useful to inform clinical practice and healthcare decision-making.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="p0265">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><label>1</label><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>H.</given-names></name><name><surname>Ferlay</surname><given-names>J.</given-names></name><name><surname>Siegel</surname><given-names>R.L.</given-names></name><name><surname>Laversanne</surname><given-names>M.</given-names></name><name><surname>Soerjomataram</surname><given-names>I.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title><source>CA Cancer J Clin</source><volume>71</volume><issue>3</issue><year>2021</year><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">33538338</pub-id></element-citation></ref><ref id="b0010"><label>2</label><mixed-citation publication-type="other" id="h0010">Ferlay J, Ervik M, Lam FC, M., Mery L, Pi&#x000f1;eros M, Znaor A et al. Global Cancer Observatory: Cancer Today. 2020. [Epub ahead of print].</mixed-citation></ref><ref id="b0015"><label>3</label><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.-P.</given-names></name><name><surname>Ismaila</surname><given-names>N.</given-names></name><name><surname>Chua</surname><given-names>M.L.K.</given-names></name><name><surname>Colevas</surname><given-names>A.D.</given-names></name><name><surname>Haddad</surname><given-names>R.</given-names></name><name><surname>Huang</surname><given-names>S.H.</given-names></name><etal/></person-group><article-title>Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline</article-title><source>J Clin Oncol</source><volume>39</volume><issue>7</issue><year>2021</year><fpage>840</fpage><lpage>859</lpage><pub-id pub-id-type="pmid">33405943</pub-id></element-citation></ref><ref id="b0020"><label>4</label><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>J.R.</given-names></name><name><surname>Parsons</surname><given-names>J.L.</given-names></name></person-group><article-title>FLASH radiotherapy: current knowledge and future insights using proton-beam therapy</article-title><source>Int J Mol Sci</source><volume>21</volume><issue>18</issue><year>2020</year><fpage>6492</fpage></element-citation></ref><ref id="b0025"><label>5</label><element-citation publication-type="journal" id="h0025"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.W.</given-names></name><name><surname>Parvathaneni</surname><given-names>U.</given-names></name><name><surname>Yom</surname><given-names>S.S.</given-names></name></person-group><article-title>Reducing radiation-related morbidity in the treatment of nasopharyngeal carcinoma</article-title><source>Future Oncol</source><volume>13</volume><issue>5</issue><year>2017</year><fpage>425</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">27875901</pub-id></element-citation></ref><ref id="b0030"><label>6</label><element-citation publication-type="journal" id="h0030"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>T.-L.</given-names></name><name><surname>Tsai</surname><given-names>M.-H.</given-names></name><name><surname>Chuang</surname><given-names>H.-C.</given-names></name><name><surname>Chien</surname><given-names>C.-Y.</given-names></name><name><surname>Lin</surname><given-names>Y.-T.</given-names></name><name><surname>Tsai</surname><given-names>W.-L.</given-names></name><etal/></person-group><article-title>Quality of life and survival outcome for patients with nasopharyngeal carcinoma treated by volumetric-modulated arc therapy versus intensity-modulated radiotherapy</article-title><source>Radiation Oncol</source><volume>15</volume><issue>1</issue><year>2020</year><fpage>84</fpage></element-citation></ref><ref id="b0035"><label>7</label><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name><surname>Desouky</surname><given-names>O.</given-names></name><name><surname>Zhou</surname><given-names>G.</given-names></name></person-group><article-title>Biophysical and radiobiological aspects of heavy charged particles</article-title><source>J Taibah Univ Sci</source><volume>10</volume><issue>2</issue><year>2016</year><fpage>187</fpage><lpage>194</lpage></element-citation></ref><ref id="b0040"><label>8</label><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name><surname>Page</surname><given-names>M.J.</given-names></name><name><surname>McKenzie</surname><given-names>J.E.</given-names></name><name><surname>Bossuyt</surname><given-names>P.M.</given-names></name><name><surname>Boutron</surname><given-names>I.</given-names></name><name><surname>Hoffmann</surname><given-names>T.C.</given-names></name><name><surname>Mulrow</surname><given-names>C.D.</given-names></name><etal/></person-group><article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title><source>BMJ</source><volume>372</volume><year>2021</year><object-id pub-id-type="publisher-id">n71</object-id></element-citation></ref><ref id="b0045"><label>9</label><mixed-citation publication-type="other" id="h0045">Barnes L, Eveson JW, Reichart P, Sidransky D. (Eds): World Health Organization Classification of Tumours. Pathology and Genetics of Head and Neck Tumors. IARC Press: Lyon 2005.</mixed-citation></ref><ref id="b0050"><label>10</label><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name><surname>Sterne</surname><given-names>J.A.</given-names></name><name><surname>Hern&#x000e1;n</surname><given-names>M.A.</given-names></name><name><surname>Reeves</surname><given-names>B.C.</given-names></name><name><surname>Savovi&#x00107;</surname><given-names>J.</given-names></name><name><surname>Berkman</surname><given-names>N.D.</given-names></name><name><surname>Viswanathan</surname><given-names>M.</given-names></name><etal/></person-group><article-title>ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions</article-title><source>BMJ</source><volume>355</volume><year>2016</year><object-id pub-id-type="publisher-id">i4919</object-id></element-citation></ref><ref id="b0055"><label>11</label><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name><surname>Gentile</surname><given-names>M.S.</given-names></name><name><surname>Yip</surname><given-names>D.</given-names></name><name><surname>Liebsch</surname><given-names>N.J.</given-names></name><name><surname>Adams</surname><given-names>J.A.</given-names></name><name><surname>Busse</surname><given-names>P.M.</given-names></name><name><surname>Chan</surname><given-names>A.W.</given-names></name></person-group><article-title>Definitive proton beam therapy for adenoid cystic carcinoma of the nasopharynx involving the base of skull</article-title><source>Oral Oncol</source><volume>65</volume><year>2017</year><fpage>38</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">28109466</pub-id></element-citation></ref><ref id="b0060"><label>12</label><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name><surname>Holliday</surname><given-names>E.B.</given-names></name><name><surname>Garden</surname><given-names>A.S.</given-names></name><name><surname>Rosenthal</surname><given-names>D.I.</given-names></name><name><surname>Fuller</surname><given-names>C.D.</given-names></name><name><surname>Morrison</surname><given-names>W.H.</given-names></name><name><surname>Gunn</surname><given-names>G.B.</given-names></name><etal/></person-group><article-title>Proton therapy reduces treatment-related toxicities for patients with nasopharyngeal cancer: a case-match control study of intensity-modulated proton therapy and intensity-modulated photon therapy</article-title><source>Int J Particle Therapy</source><volume>2</volume><issue>1</issue><year>2015</year><fpage>19</fpage><lpage>28</lpage></element-citation></ref><ref id="b0065"><label>13</label><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name><surname>Sanford</surname><given-names>N.N.</given-names></name><name><surname>Lau</surname><given-names>J.</given-names></name><name><surname>Lam</surname><given-names>M.B.</given-names></name><name><surname>Juliano</surname><given-names>A.F.</given-names></name><name><surname>Adams</surname><given-names>J.A.</given-names></name><name><surname>Goldberg</surname><given-names>S.I.</given-names></name><etal/></person-group><article-title>Individualization of clinical target volume delineation based on stepwise spread of nasopharyngeal carcinoma: outcome of more than a decade of clinical experience</article-title><source>Int J Radiat Oncol*Biol*Phys</source><volume>103</volume><issue>3</issue><year>2019</year><fpage>654</fpage><lpage>668</lpage><pub-id pub-id-type="pmid">30712708</pub-id></element-citation></ref><ref id="b0070"><label>14</label><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name><surname>Sasidharan</surname><given-names>B.K.</given-names></name><name><surname>Aljabab</surname><given-names>S.</given-names></name><name><surname>Saini</surname><given-names>J.</given-names></name><name><surname>Wong</surname><given-names>T.</given-names></name><name><surname>Laramore</surname><given-names>G.</given-names></name><name><surname>Liao</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Clinical Monte Carlo versus pencil beam treatment planning in nasopharyngeal patients receiving IMPT</article-title><source>Int J Particle Therapy</source><volume>5</volume><issue>4</issue><year>2019</year><fpage>32</fpage><lpage>40</lpage></element-citation></ref><ref id="b0075"><label>15</label><element-citation publication-type="journal" id="h0075"><person-group person-group-type="author"><name><surname>Shusharina</surname><given-names>N.</given-names></name><name><surname>Fullerton</surname><given-names>B.</given-names></name><name><surname>Adams</surname><given-names>J.A.</given-names></name><name><surname>Sharp</surname><given-names>G.C.</given-names></name><name><surname>Chan</surname><given-names>A.W.</given-names></name></person-group><article-title>Impact of aeration change and beam arrangement on the robustness of proton plans</article-title><source>J Appl Clin Med Phys</source><volume>20</volume><issue>3</issue><year>2019</year><fpage>14</fpage><lpage>21</lpage></element-citation></ref><ref id="b0080"><label>16</label><element-citation publication-type="journal" id="h0080"><person-group person-group-type="author"><name><surname>Uezono</surname><given-names>H.</given-names></name><name><surname>Indelicato</surname><given-names>D.J.</given-names></name><name><surname>Rotondo</surname><given-names>R.L.</given-names></name><name><surname>Sandler</surname><given-names>E.S.</given-names></name><name><surname>Katzenstein</surname><given-names>H.M.</given-names></name><name><surname>Dagan</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Proton therapy following induction chemotherapy for pediatric and adolescent nasopharyngeal carcinoma</article-title><source>Pediatr Blood Cancer</source><volume>66</volume><issue>12</issue><year>2019</year><object-id pub-id-type="publisher-id">e27990</object-id></element-citation></ref><ref id="b0085"><label>17</label><element-citation publication-type="journal" id="h0085"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>V.M.</given-names></name><name><surname>Parvathaneni</surname><given-names>U.</given-names></name><name><surname>Laramore</surname><given-names>G.E.</given-names></name><name><surname>Aljabab</surname><given-names>S.</given-names></name><name><surname>Wong</surname><given-names>T.P.</given-names></name><name><surname>Liao</surname><given-names>J.J.</given-names></name></person-group><article-title>Intensity-modulated proton therapy for nasopharynx cancer: 2-year outcomes from a single institution</article-title><source>Int J Part Ther</source><volume>8</volume><issue>2</issue><year>2021</year><fpage>28</fpage><lpage>40</lpage></element-citation></ref><ref id="b0090"><label>18</label><element-citation publication-type="journal" id="h0090"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.Y.</given-names></name><name><surname>Huo</surname><given-names>W.L.</given-names></name><name><surname>Goldberg</surname><given-names>S.I.</given-names></name><name><surname>Slater</surname><given-names>J.M.</given-names></name><name><surname>Adams</surname><given-names>J.A.</given-names></name><name><surname>Deng</surname><given-names>X.-W.</given-names></name><etal/></person-group><article-title>Brain-specific relative biological effectiveness of protons based on long-term outcome of patients with nasopharyngeal carcinoma</article-title><source>Int J Radiat Oncol*Biol*Phys</source><volume>110</volume><issue>4</issue><year>2021</year><fpage>984</fpage><lpage>992</lpage><pub-id pub-id-type="pmid">33600889</pub-id></element-citation></ref><ref id="b0095"><label>19</label><element-citation publication-type="journal" id="h0095"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Kitpanit</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>A.</given-names></name><name><surname>Mah</surname><given-names>D.</given-names></name><name><surname>Sine</surname><given-names>K.</given-names></name><name><surname>Sherman</surname><given-names>E.J.</given-names></name><etal/></person-group><article-title>Toxicity profiles and survival outcomes among patients with nonmetastatic nasopharyngeal carcinoma treated with intensity-modulated proton therapy vs intensity-modulated radiation therapy</article-title><source>JAMA Network Open</source><volume>4</volume><issue>6</issue><year>2021</year><fpage>e2113205</fpage><pub-id pub-id-type="pmid">34143193</pub-id></element-citation></ref><ref id="b0100"><label>20</label><element-citation publication-type="journal" id="h0100"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Bao</surname><given-names>C.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Guan</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Salvage treatment using carbon ion radiation in patients with locoregionally recurrent nasopharyngeal carcinoma: Initial results</article-title><source>Cancer</source><volume>124</volume><issue>11</issue><year>2018</year><fpage>2427</fpage><lpage>2437</lpage><pub-id pub-id-type="pmid">29579324</pub-id></element-citation></ref><ref id="b0105"><label>21</label><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>Q.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Guan</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Clinical outcomes of carbon-ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma</article-title><source>Cancer</source><volume>126</volume><issue>23</issue><year>2020</year><fpage>5173</fpage><lpage>5183</lpage><pub-id pub-id-type="pmid">32931035</pub-id></element-citation></ref><ref id="b0110"><label>22</label><element-citation publication-type="journal" id="h0110"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>Q.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Guan</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Mixed photon and carbon-ion beam radiotherapy in the management of non-metastatic nasopharyngeal carcinoma</article-title><source>Front Oncol</source><volume>11</volume><issue>2894</issue><year>2021</year></element-citation></ref><ref id="b0115"><label>23</label><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Qiu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Volumetric parameters derived from FLT-PET performed at completion of treatment predict efficacy of Carbon-ion Radiotherapy in patients with locally recurrent Nasopharyngeal Carcinoma</article-title><source>J Cancer</source><volume>11</volume><issue>23</issue><year>2020</year><fpage>7073</fpage><lpage>7080</lpage><pub-id pub-id-type="pmid">33123296</pub-id></element-citation></ref><ref id="b0120"><label>24</label><element-citation publication-type="journal" id="h0120"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>G.</given-names></name><name><surname>Gu</surname><given-names>B.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Kong</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Pretreatment 18F-FDG uptake heterogeneity can predict treatment outcome of carbon ion radiotherapy in patients with locally recurrent nasopharyngeal carcinoma</article-title><source>Ann Nucl Med</source><volume>35</volume><issue>7</issue><year>2021</year><fpage>834</fpage><lpage>842</lpage><pub-id pub-id-type="pmid">33913102</pub-id></element-citation></ref><ref id="b0125"><label>25</label><element-citation publication-type="journal" id="h0125"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Kong</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>J.J.</given-names></name></person-group><article-title>Intensity-modulated carbon-ion radiation therapy versus intensity-modulated photon-based radiation therapy in locally recurrent nasopharyngeal carcinoma: a dosimetric comparison</article-title><source>Cancer Manag Res</source><volume>11</volume><year>2019</year><fpage>7767</fpage><lpage>7777</lpage><pub-id pub-id-type="pmid">31496819</pub-id></element-citation></ref><ref id="b0130"><label>26</label><element-citation publication-type="journal" id="h0130"><person-group person-group-type="author"><name><surname>Akbaba</surname><given-names>S.</given-names></name><name><surname>Ahmed</surname><given-names>D.</given-names></name><name><surname>Lang</surname><given-names>K.</given-names></name><name><surname>Held</surname><given-names>T.</given-names></name><name><surname>Mattke</surname><given-names>M.</given-names></name><name><surname>Hoerner-Rieber</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Results of a combination treatment with intensity modulated radiotherapy and active raster-scanning carbon ion boost for adenoid cystic carcinoma of the minor salivary glands of the nasopharynx</article-title><source>Oral Oncol</source><volume>91</volume><year>2019</year><fpage>39</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">30926061</pub-id></element-citation></ref><ref id="b0135"><label>27</label><element-citation publication-type="journal" id="h0135"><person-group person-group-type="author"><name><surname>Akbaba</surname><given-names>S.</given-names></name><name><surname>Held</surname><given-names>T.</given-names></name><name><surname>Lang</surname><given-names>K.</given-names></name><name><surname>Forster</surname><given-names>T.</given-names></name><name><surname>Federspil</surname><given-names>P.</given-names></name><name><surname>Herfarth</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Bimodal radiotherapy with active raster-scanning carbon ion radiotherapy and intensity-modulated radiotherapy in high-risk nasopharyngeal carcinoma results in excellent local control</article-title><source>Cancers</source><volume>11</volume><issue>3</issue><year>2019</year><fpage>379</fpage></element-citation></ref><ref id="b0140"><label>28</label><element-citation publication-type="journal" id="h0140"><person-group person-group-type="author"><name><surname>Alterio</surname><given-names>D.</given-names></name><name><surname>D&#x02019;Ippolito</surname><given-names>E.</given-names></name><name><surname>Vischioni</surname><given-names>B.</given-names></name><name><surname>Fossati</surname><given-names>P.</given-names></name><name><surname>Gandini</surname><given-names>S.</given-names></name><name><surname>Bonora</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Mixed-beam approach in locally advanced nasopharyngeal carcinoma: IMRT followed by proton therapy boost versus IMRT-only. Evaluation of toxicity and efficacy</article-title><source>Acta Oncol</source><volume>59</volume><issue>5</issue><year>2020</year><fpage>541</fpage><lpage>548</lpage><pub-id pub-id-type="pmid">32090645</pub-id></element-citation></ref><ref id="b0145"><label>29</label><element-citation publication-type="journal" id="h0145"><person-group person-group-type="author"><name><surname>Dionisi</surname><given-names>F.</given-names></name><name><surname>Croci</surname><given-names>S.</given-names></name><name><surname>Giacomelli</surname><given-names>I.</given-names></name><name><surname>Cianchetti</surname><given-names>M.</given-names></name><name><surname>Caldara</surname><given-names>A.</given-names></name><name><surname>Bertolin</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Clinical results of proton therapy reirradiation for recurrent nasopharyngeal carcinoma</article-title><source>Acta Oncol</source><volume>58</volume><issue>9</issue><year>2019</year><fpage>1238</fpage><lpage>1245</lpage><pub-id pub-id-type="pmid">31155998</pub-id></element-citation></ref><ref id="b0150"><label>30</label><element-citation publication-type="journal" id="h0150"><person-group person-group-type="author"><name><surname>Abe</surname><given-names>T.</given-names></name><name><surname>Ohno</surname><given-names>T.</given-names></name><name><surname>Koto</surname><given-names>M.</given-names></name><name><surname>Demizu</surname><given-names>Y.</given-names></name><name><surname>Suefuji</surname><given-names>H.</given-names></name><name><surname>Tsuji</surname><given-names>H.</given-names></name><etal/></person-group><article-title>A multi-institutional retrospective study of carbon-ion radiotherapy for non-squamous cell malignant tumors of the nasopharynx: Subanalysis of Japan Carbon-Ion Radiation Oncology Study Group study 1402 HN</article-title><source>Cancer Med</source><volume>7</volume><issue>12</issue><year>2018</year><fpage>6077</fpage><lpage>6083</lpage><pub-id pub-id-type="pmid">30449067</pub-id></element-citation></ref><ref id="b0155"><label>31</label><element-citation publication-type="journal" id="h0155"><person-group person-group-type="author"><name><surname>Minatogawa</surname><given-names>H.</given-names></name><name><surname>Yasuda</surname><given-names>K.</given-names></name><name><surname>Dekura</surname><given-names>Y.</given-names></name><name><surname>Takao</surname><given-names>S.</given-names></name><name><surname>Matsuura</surname><given-names>T.</given-names></name><name><surname>Yoshimura</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Potential benefits of adaptive intensity-modulated proton therapy in nasopharyngeal carcinomas</article-title><source>J Appl Clin Med Phys</source><volume>22</volume><issue>1</issue><year>2021</year><fpage>174</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">33338323</pub-id></element-citation></ref><ref id="b0160"><label>32</label><element-citation publication-type="journal" id="h0160"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>H.</given-names></name><name><surname>Ahn</surname><given-names>Y.C.</given-names></name><name><surname>Yang</surname><given-names>K.</given-names></name><name><surname>Oh</surname><given-names>D.</given-names></name><name><surname>Noh</surname><given-names>J.M.</given-names></name></person-group><article-title>Re-irradiation with moderate hypo-fractionation using intensity modulated photon or proton radiation therapy in locally recurrent squamous cell carcinoma of nasopharynx</article-title><source>J Korean Cancer Assoc</source><year>2021</year></element-citation></ref><ref id="b0165"><label>33</label><element-citation publication-type="journal" id="h0165"><person-group person-group-type="author"><name><surname>Park</surname><given-names>S.G.</given-names></name><name><surname>Ahn</surname><given-names>Y.C.</given-names></name><name><surname>Oh</surname><given-names>D.</given-names></name><name><surname>Noh</surname><given-names>J.M.</given-names></name><name><surname>Ju</surname><given-names>S.G.</given-names></name><name><surname>Kwon</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Early clinical outcomes of helical tomotherapy/intensity-modulated proton therapy combination in nasopharynx cancer</article-title><source>Cancer Sci</source><volume>110</volume><issue>9</issue><year>2019</year><fpage>2867</fpage><lpage>2874</lpage><pub-id pub-id-type="pmid">31237050</pub-id></element-citation></ref><ref id="b0170"><label>34</label><element-citation publication-type="journal" id="h0170"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>Y.-C.</given-names></name><name><surname>Fan</surname><given-names>K.-H.</given-names></name><name><surname>Lin</surname><given-names>C.-Y.</given-names></name><name><surname>Hung</surname><given-names>T.-M.</given-names></name><name><surname>Huang</surname><given-names>B.-S.</given-names></name><name><surname>Chang</surname><given-names>K.-P.</given-names></name><etal/></person-group><article-title>Intensity modulated proton beam therapy versus volumetric modulated arc therapy for patients with nasopharyngeal cancer: a propensity score-matched study</article-title><source>Cancers</source><volume>13</volume><issue>14</issue><year>2021</year><fpage>3555</fpage><pub-id pub-id-type="pmid">34298769</pub-id></element-citation></ref><ref id="b0175"><label>35</label><element-citation publication-type="journal" id="h0175"><person-group person-group-type="author"><name><surname>Ji&#x00159;&#x000ed;</surname><given-names>K.</given-names></name><name><surname>Vladim&#x000ed;r</surname><given-names>V.</given-names></name><name><surname>Michal</surname><given-names>A.</given-names></name><name><surname>Mat&#x0011b;j</surname><given-names>N.</given-names></name><name><surname>Silvia</surname><given-names>S.</given-names></name><name><surname>Pavel</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Proton pencil-beam scanning radiotherapy in the treatment of nasopharyngeal cancer: dosimetric parameters and 2-year results</article-title><source>Eur Arch Otorhinolaryngol</source><volume>278</volume><issue>3</issue><year>2021</year><fpage>763</fpage><lpage>769</lpage><pub-id pub-id-type="pmid">32623508</pub-id></element-citation></ref><ref id="b0180"><label>36</label><element-citation publication-type="journal" id="h0180"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>H.M.</given-names></name><name><surname>Chan</surname><given-names>O.C.M.</given-names></name><name><surname>Mak</surname><given-names>C.H.</given-names></name><name><surname>Hung</surname><given-names>W.M.</given-names></name><name><surname>Ng</surname><given-names>W.T.</given-names></name><name><surname>Lee</surname><given-names>M.C.H.</given-names></name></person-group><article-title>Dosimetric comparison of intensity modulated radiotherapy and intensity modulated proton therapy in the treatment of recurrent nasopharyngeal carcinoma</article-title><source>Med Dosim</source><year>2021</year></element-citation></ref><ref id="b0185"><label>37</label><mixed-citation publication-type="other" id="h0185">National Comprehensive Cancer Network. Head and Neck Cancers (Version 1.2022). In. National Comprehensive Cancer Network, 2022.</mixed-citation></ref><ref id="b0190"><label>38</label><element-citation publication-type="journal" id="h0190"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Dong</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Kong</surname><given-names>L.</given-names></name><name><surname>Lu</surname><given-names>J.J.</given-names></name></person-group><article-title>Comparison of the effects of photon, proton and carbon-ion radiation on the ecto-calreticulin exposure in various tumor cell lines</article-title><source>Ann Transl Med</source><volume>7</volume><issue>20</issue><year>2019</year><fpage>542</fpage><pub-id pub-id-type="pmid">31807524</pub-id></element-citation></ref><ref id="b0195"><label>39</label><element-citation publication-type="journal" id="h0195"><person-group person-group-type="author"><name><surname>Blanchard</surname><given-names>P.</given-names></name><name><surname>Volk</surname><given-names>R.J.</given-names></name><name><surname>Ringash</surname><given-names>J.</given-names></name><name><surname>Peterson</surname><given-names>S.K.</given-names></name><name><surname>Hutcheson</surname><given-names>K.A.</given-names></name><name><surname>Frank</surname><given-names>S.J.</given-names></name></person-group><article-title>Assessing head and neck cancer patient preferences and expectations: a systematic review</article-title><source>Oral Oncol</source><volume>62</volume><year>2016</year><fpage>44</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">27865371</pub-id></element-citation></ref><ref id="b0200"><label>40</label><element-citation publication-type="journal" id="h0200"><person-group person-group-type="author"><name><surname>Gourin</surname><given-names>C.G.</given-names></name></person-group><article-title>Outcomes measurement in patients with head and neck cancer</article-title><source>Curr Oncol Reports</source><volume>16</volume><issue>3</issue><year>2014</year><fpage>376</fpage></element-citation></ref><ref id="b0205"><label>41</label><element-citation publication-type="journal" id="h0205"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Xia</surname><given-names>Y.-F.</given-names></name><name><surname>Huang</surname><given-names>Y.-X.</given-names></name><name><surname>Okat</surname><given-names>D.</given-names></name><name><surname>Qiu</surname><given-names>B.</given-names></name><name><surname>Doyen</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Intensity-modulated proton radiation therapy as a radical treatment modality for nasopharyngeal carcinoma in China: Cost-effectiveness analysis</article-title><source>Head Neck</source><volume>44</volume><issue>2</issue><year>2022</year><fpage>431</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">34837286</pub-id></element-citation></ref><ref id="b0210"><label>42</label><mixed-citation publication-type="other" id="h0210">Kim J, Wells C, Khangura S, Alexander C, Mulla S, Farrah K et al. Proton Beam Therapy for the Treatment of Cancer in Children and Adults: A Health Technology Assessment [Internet]. CADTH Health Technology Assessments, No. 145. Ottawa (ON): Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017.</mixed-citation></ref><ref id="b0215"><label>43</label><element-citation publication-type="journal" id="h0215"><person-group person-group-type="author"><name><surname>Peeters</surname><given-names>A.</given-names></name><name><surname>Grutters</surname><given-names>J.P.</given-names></name><name><surname>Pijls-Johannesma</surname><given-names>M.</given-names></name><name><surname>Reimoser</surname><given-names>S.</given-names></name><name><surname>De Ruysscher</surname><given-names>D.</given-names></name><name><surname>Severens</surname><given-names>J.L.</given-names></name><etal/></person-group><article-title>How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons</article-title><source>Radiother Oncol</source><volume>95</volume><issue>1</issue><year>2010</year><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">20106540</pub-id></element-citation></ref><ref id="b0220"><label>44</label><element-citation publication-type="journal" id="h0220"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>V.</given-names></name><name><surname>Mishra</surname><given-names>M.V.</given-names></name><name><surname>Mehta</surname><given-names>M.P.</given-names></name></person-group><article-title>A systematic review of the cost and cost-effectiveness studies of proton radiotherapy</article-title><source>Cancer</source><volume>122</volume><issue>10</issue><year>2016</year><fpage>1483</fpage><lpage>1501</lpage><pub-id pub-id-type="pmid">26828647</pub-id></element-citation></ref><ref id="b0225"><label>45</label><element-citation publication-type="journal" id="h0225"><person-group person-group-type="author"><name><surname>Tambas</surname><given-names>M.</given-names></name><name><surname>van der Laan</surname><given-names>H.P.</given-names></name><name><surname>van der Schaaf</surname><given-names>A.</given-names></name><name><surname>Steenbakkers</surname><given-names>R.J.H.M.</given-names></name><name><surname>Langendijk</surname><given-names>J.A.</given-names></name></person-group><article-title>A decision support tool to optimize selection of head and neck cancer patients for proton therapy</article-title><source>Cancers</source><volume>14</volume><issue>3</issue><year>2022</year><fpage>681</fpage><pub-id pub-id-type="pmid">35158949</pub-id></element-citation></ref></ref-list><sec id="s0120" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0275">The following are the Supplementary data to this article:<supplementary-material content-type="local-data" id="m0025"><caption><title>Supplementary data 1</title></caption><media xlink:href="mmc1.docx"/></supplementary-material></p><p id="p0280">
<supplementary-material content-type="local-data" id="m0020"><caption><title>Supplementary data 2</title></caption><media xlink:href="mmc2.docx"/></supplementary-material>
</p><p id="p0285">
<supplementary-material content-type="local-data" id="m0015"><caption><title>Supplementary data 3</title></caption><media xlink:href="mmc3.docx"/></supplementary-material>
</p><p id="p0290">
<supplementary-material content-type="local-data" id="m0010"><caption><title>Supplementary data 4</title></caption><media xlink:href="mmc4.docx"/></supplementary-material>
</p><p id="p0295">
<supplementary-material content-type="local-data" id="m0005"><caption><title>Supplementary data 5</title></caption><media xlink:href="mmc5.docx"/></supplementary-material>
</p></sec><ack id="ack900"><title>Acknowledgements</title><p id="p9055">This paper received no external funding. W.T. Ng and Anne W.M. Lee are supported by the Shenzhen Fundamental Research Program, China (JCYJ20210324114404013). Melvin L.K. Chua is supported by the National Medical Research Council Singapore Clinician Scientist Award (NMRC/CSA-INV/0027/2018, CSAINV20nov-0021), the Duke-NUS Oncology Academic Program Goh Foundation Proton Research Programme, NCCS Cancer Fund, and the Kua Hong Pak Head and Neck Cancer Research Programme.</p></ack><fn-group><fn id="s0115" fn-type="supplementary-material"><label>Appendix A</label><p id="p0270">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ctro.2022.08.011" id="ir005">https://doi.org/10.1016/j.ctro.2022.08.011</ext-link>.</p></fn></fn-group></back></article>
